Therapeutic antibodies
Antibodies targeting CD161+ cells without blocking CLEC2D binding offer a selective treatment for IMIDs, effectively reducing inflammation without compromising immune function.
Patent Information
- Application Number
- PCT/EP2026/064159
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-14
- Filing Date
- 2026-05-14
- Publication Date
- 2026-11-19
AI Technical Summary
Current treatments for immune-mediated inflammatory diseases (IMIDs) do not address the underlying cause and can weaken the immune system, increasing susceptibility to infections and cancer, while broad immune depletive therapies pose safety concerns.
Development of antibodies and antigen binding fragments that specifically target CD161+ cells without significantly inhibiting CD161-CLEC2D binding, allowing for selective depletion of these cells to reduce pro-inflammatory cytokine production without impairing immune function.
The antibodies effectively deplete CD161+ cells, reducing pro-inflammatory cytokines while maintaining immune system functionality by preserving CD161-CLEC2D interaction, thus providing a targeted therapeutic approach for IMIDs.
Smart Images

Figure IMGF000047_0001 
Figure IMGF000066_0001 
Figure IMGF000073_0001_TABLE
Abstract
Description
[0001] THERAPEUTIC ANTIBODIES
[0002] FIELD OF THE INVENTION
[0003] The present invention relates to methods, compositions, antibodies and antigen binding fragments for treating immune-mediated inflammatory diseases (IMIDs) via the targeted depletion of CD161+ cells.
[0004] BACKGROUND
[0005] Immune-mediated inflammatory diseases (IMIDs) are clinically diverse diseases characterised by immune system dysregulation, promoting inflammation and tissue damage.
[0006] Current treatment strategies for IMIDs aim to reduce inflammation, alleviate symptoms, and slow disease progression. Traditional approaches include nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, as well as more targeted biologic therapies.
[0007] More specifically, in the last few decades, biologic therapies have revolutionized the management of IMIDs. These targeted treatments are designed to interfere with specific components of the immune system. For example, tumor necrosis factor (TNF) inhibitors like infliximab and adalimumab block the activity of TNFa, a key pro-inflammatory cytokine. Similarly, interleukin (IL) inhibitors, such as ustekinumab and secukinumab, target other cytokines involved in inflammation.
[0008] Janus kinase (JAK) inhibitors represent another class of targeted therapies. These small molecules inhibit the JAK-STAT signalling pathway, which plays a crucial role in immune cell activation. Drugs like tofacitinib, baricitinib, upadacitinib have shown efficacy in treating conditions like rheumatoid arthritis, atopic dermatitis and psoriasis.
[0009] However, while these therapies improve the management of IMIDs, they do not address the underlying cause. Consequently, patients suffering from IMIDs require ongoing treatment which can weaken the immune system and increase susceptibility to infection as well as cancer.
[0010] Attempts to cure IMIDs have also been made using broad immune depletive therapies. However, while these therapies have demonstrated the potential to cure certain autoimmune diseases, serious concerns remain regarding the safety issues arising from the depletion of entire immune cell populations.Thus, there is a need in the art for targeted therapeutics for the treatment and prevention of autoimmune diseases which selectively deplete pathogenic immune cells, resetting the immune system without the associated safety concerns.
[0011] SUMMARY OF THE INVENTION
[0012] In one aspect, the present invention provides an antibody molecule or antigen binding fragment which binds to and depletes CD161+ cells and which does not significantly inhibit CD161-CLEC2D binding. The antibody molecule or antigen binding fragment of the invention binds specifically to CD161.
[0013] In one aspect, the present invention provides a polypeptide which binds to CD161, depletes CD161+ cells and which does not significantly inhibit CD161-CLEC2D binding. The polypeptide may be any one of the antibody molecules or antigen binding fragments described herein, for example comprising one of more of the sequences disclosed in Table 7 or Table 8.
[0014] In one aspect, the present invention provides an anti-CD161 antibody comprising:
[0015] a) a means for binding CD161; and
[0016] b) an Fc region;
[0017] wherein the anti-CD161 antibody is capable of depleting CD161+ cells without significantly inhibiting CD161-CLEC2D binding. The means for binding anti CD161 may be any of the antibody sequences disclosed herein, for example the CDR combinations in Table 7 or the VH / VL combinations in Table 8. CD161 is a type II transmembrane C-type lectin receptor expressed on the surface of various lymphocytes in both the adaptive and innate immune systems. CD161 is encoded by the KLRB1 gene and is also known as NKR-P1A. CD161 naturally presents as a 40kDa homodimer comprised of two monomer subunits joined via disulfide linkages in the extracellular domain.
[0018] The present inventors have identified that that KLRB1 (CD161) expressing cells are causal drivers of IL-17 / 23 driven IMIDs. Based on this discovery, anti-CD161 antibodies and antigen binding fragments were developed which can bind to and deplete CD161+ cells. Importantly, these antibodies do not significantly compete with CLEC2D-CD161 binding.
[0019] CLEC2D (C-type lectin domain family 2 member D) is the primary natural ligand of CD161 and is also known as LLT1. CLEC2D is primarily located on the cell membrane and contains a C-type lectin-like extracellular domain and a transmembrane domain near the N-terminus. CLEC2D has been found to be expressed on tumor cells, infiltrating bone marrow cells, monocytes, natural killer (NK) cells, and subsets of T cells.The interaction between CD161 and its natural ligand, CLEC2D, inhibits T cell activation. The antibodies and antigen binding fragments of the present invention do not block the interaction between CLEC2D and CD161, meaning CLEC2D is still able to bind to CD161 and suppress T cell activation. As those skilled in the art will recognise, this inhibition of T cell activation has an immune-damping effect and thus, by minimising or avoiding competition with CLEC2D / CD161 binding, the antibodies or antigen binding fragments of the present invention permit this immune-damping effect to occur, contributing to their efficacy in the treatment and prevention of IM IDs.
[0020] As is demonstrated in the accompanying examples, specific antibodies exhibiting this beneficial combination of properties have been developed by the inventors. Thus, in embodiments of the invention, the antibody or antigen-binding fragment comprises one, two or three heavy chain complementarity determining regions selected from SEQ ID NOs. 1, 2, 3, 7, 8, 9, 13, 14, 15, 19, 20, 21, 25, 26, T1 , 31, 32, 33, 37, 38, 39, 43, 44, 45, 49, 50, 51, 55, 56, 57, 61, 62, 63, 67, 68, 69, 73, 74, 75, 79, 80, 81, 85, 86, 872, 260, 261, 262, 266, 267, 268, 276, Til , 278, 282, 283, 284, 288, 289, 290, 294, 295, 296, 300, 301, 302, 306, 307, 308, 312, 313, 314, 318, 319, 320, 324, 325, 326, 348, 349, 350, 354, or 356. Additionally, or alternatively, the antibody or antigen-binding fragment may comprise one, two or three light chain complementarity determining regions selected from SEQ ID NOs. 4, 5, 6, 10, 11, 12, 16, 17, 18, 22, 23, 24, 28, 29, 30, 34, 35, 36, 40, 41, 42, 46, 47, 48, 52, 53, 54, 58, 59, 60, 64, 65, 66, 70, 71, 72, 76, 77, 78, 82, 83, 84, 88, 89, 90, 263, 264, 265, 269, 270, 271, 279, 280, 281, 285, 286, 287, 291, 292, 293, 297, 298, 299, 303, 304, 305, 309, 310, 311, 315, 316, 317, 321, 322, 323, 327, 328, 329, 351, 352, 353 or 355.
[0021] In some embodiments of the invention, the antibody or antigen-binding fragment comprises one, two or three heavy chain complementarity determining regions selected from SEQ ID NOs. 1, 2, 3, 7, 8, 9, 13, 14, 15, 19, 20, 21, 25, 26, T1 , 31, 32, 33, 37, 38, 39, 43, 44, 45, 49, 50, 51, 55, 56, 57, 61, 62, 63, 67, 68, 69, 73, 74, 75, 79, 80, 81, 85, 86, 872, 260, 261, 262, 266, 267, 268, 348, 349, 350, 354, or 356. Additionally, or alternatively, the antibody or antigen-binding fragment may comprise one, two or three light chain complementarity determining regions selected from SEQ ID NOs. 4, 5, 6, 10, 11, 12, 16, 17, 18, 22, 23, 24, 28, 29, 30, 34, 35, 36, 40, 41, 42, 46, 47, 48, 52, 53, 54, 58, 59, 60, 64, 65, 66, 70, 71, 72, 76, 77, 78, 82, 83, 84, 88, 89, 90, 263, 264, 265, 269, 270,271, 351, 352, 353 or 355.
[0022] In certain embodiments of the invention, the antibody or antigen-binding fragment comprises one, two or three heavy chain complementarity determining regions selected from SEQ ID NOs. 1, 2, 3, 25, 26, T1 , 37, 38, 39, 61, 62, 63, 67, 68, 69, 73, 74, 75, 260, 261, 262, 266, 267, 268, 348, 349, 350, 354, or 356. Additionally, or alternatively, the antibody or antigen-binding fragment may comprise one, two or threelight chain complementarity determining regions selected from SEQ ID NOs. 4, 5, 6, 28, 29, 30, 40, 41, 42, 64, 65, 66, 70, 71, 72, 76, 77, 78, 263, 264, 265, 269, 270, 271, 351, 352, 353 or 355.
[0023] In certain embodiments, the antibody or antigen-binding fragment comprises a VHCDR combination and / or a VLCDR combination included in Table 7 below. In some embodiments, the antibody or antigenbinding fragment comprises the VHCDR and VLCDR combinations for clones 15, 32, 58, 181, 17, 36, 45, 52, 65, 128, 145, 190, 191, 231, 255, 11, 123, 282, 31, 75, 171, 185, 212, 240 or humanized variants shown in Table 7 below.
[0024] In some embodiments, the antibody or antigen-binding fragment comprises the VHCDR and VLCDR combinations for clones 15, 32, 58, 181, 17, 36, 45, 52, 65, 128, 145, 190, 191, 231, 255, 11, 123 or humanized variants shown in Table 7 below.
[0025] In certain embodiments, the antibody or antigen-binding fragment comprises the VHCDR and VLCDR combinations for clones 11, 15, 17, 45, 123, 145, 190, 191 and / or humanized variants shown in Table 7 below.
[0026] In certain embodiments of the invention, the antibody or antigen-binding fragment comprises a heavy chain variable region (VH) comprising an amino acid sequence which has at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98% or at least about 99% identity to SEQ ID NOS. 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 272, 274, 330, 332, 334, 336, 338, 340, 342, 344, 346, 357 or 358. Additionally or alternatively, in embodiments of the invention, the antibody or antigen-binding fragment may comprise a light chain variable region (VL) comprising an amino acid sequence which has at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98% or at least about 99% identity to SEQ ID NOS.
[0027] 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 273, 275, 331, 333, 335, 337, 339, 341, 343, 345,347, 359, 360, 361, or 362.
[0028] In some embodiments of the invention, the antibody or antigen-binding fragment comprises a heavy chain variable region (VH) comprising an amino acid sequence which has at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98% or at least about 99% identity to SEQ ID NOS. 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 272, 274, 357 or 358. Additionally or alternatively, in embodiments of the invention, the antibody or antigen-binding fragment may comprise a light chain variable region (VL) comprising an amino acid sequence which has at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, at leastabout 98% or at least about 99% identity to SEQ ID NOS. 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 273, or 275, 359, 360, 361, or 362.
[0029] In some embodiments of the invention, the antibody or antigen-binding fragment comprises a heavy chain variable region (VH) comprising an amino acid sequence which has at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98% or at least about 99% identity to SEQ ID NOS. 91, 99, 103, 111, 113, 115, 272, 274, 357 or 358. Additionally or alternatively, in embodiments of the invention, the antibody or antigen-binding fragment may comprise a light chain variable region (VL) comprising an amino acid sequence which has at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98% or at least about 99% identity to SEQ ID NOS. 92, 100, 104, 112, 114, 116, 273, 275, 359, 360, 361, or 362.
[0030] In some embodiments, the antibody or antigen-binding fragment comprises the VH and VL combinations for clones 15, 32, 58, 181, 17, 36, 45, 52, 65, 128, 145, 190, 191, 231, 255, 11, 123, 282, 31, 75, 171, 185, 212, 240, 293, 561, REA-001_A_019, REA-00 l_A_020, REA-001_A_021, REA-001_A_022, REA-00 l_A_023, REA-001_A_024, REA-001_A_025, or REA-001_A_026 shown in Table 8 below.
[0031] In embodiments, the antibody or antigen-binding fragment comprises the VH and VL combinations for clones 15, 32, 58, 181, 17, 36, 45, 52, 65, 128, 145, 190, 191, 231, 255, 11, or 123 shown in Table 8 below.
[0032] In embodiments, the antibody or antigen-binding fragment comprises the VH and VL combinations for clones 11, 15, 17, 45, 123, 145, 190, and / or 191 shown in Table 8 below.
[0033] In embodiments, the antibody or antigen-binding fragment comprises the VH and VL combinations for clones REA-001_A_019, REA-001_A_020, REA-001_A_021, REA-001_A_022, REA-001_A_023, REA-001_A_024, REA-001_A_025, and / or REA-001_A_026 shown in Table 8 below.
[0034] In further aspects of the invention, there is provided a nucleic acid encoding an antibody molecule or antigen binding fragment according to the present invention, an expression vector comprising such a nucleic acid and a host cell comprising such an expression vector.
[0035] Also provided herein is a pharmaceutical composition comprising an antibody molecule or antigen binding fragment according to the present invention, a nucleic acid according to the present invention, an expression vector to the present invention, and / or a host cell of the present invention and optionally one or more pharmaceutically acceptable excipients, diluents or carriers.As explained herein, as a result of their ability to deplete CD161+ cells while only modestly (at most) competing with CLEC2D / CD161 binding, the antibodies do not augment T cell activation and proinflammatory cytokine production, thus making them effective treatments for IMIDs. Thus, according to a further aspect of the present invention, there is provided an antibody molecule or antigen binding fragment, a nucleic acid, an expression vector, a host cell or a pharmaceutical composition of the present invention for use in treating or preventing an I M ID.
[0036] In embodiments of the invention, the IMID may be an autoimmune disease, for example hidradenitis suppurativa, psoriasis (PsO), psoriatic Arthritis (PsA), axial spondyloarthritis (AxSpA), Crohn's disease, ulcerative colitis or uveitis.
[0037] Various aspects of the invention are described in further detail below.
[0038] BRIEF DESCRIPTION OF THE FIGURES
[0039] Embodiments of the invention are further described hereinafter with reference to the accompanying drawings, in which:
[0040] Figures 1A to D provide Uniform Manifold Approximation and Projections (UMAPs) of lesion samples collected from patients with HS and psoriasis, and IL17A and IL17F expression profiles of the cells;
[0041] Figures 2A-C provide dot plots of the percent expressed, and average expression of pro- inflammatory cytokines and chemokines. IL-17 expression was restricted to the CD161+ T cell subset (Figure 2A) and expression of broader proinflammatory mediators was analysed in HS (Figure 2B) and PsO (Figure 2C) lesional skin tissue;
[0042] Figure 3 provides flow cytometry data of polyclonally activated T cells from healthy PBMCs and expression of CD161 and IL-17A / F (Figure 3A). The frequency of CD161+ and CD161- T cells expressing I L-17A / F across six healthy donors is shown in Figure 3B;
[0043] Figure 4 provides a gating strategy to identify NK cells, MAIT cells and Thl7 cells from healthy human PBMCs;
[0044] Figure 5 depicts the geometric mean expression of CD161 by Thl7, MAIT and NK cells across six healthy donors;Figure 6 provides binding data for mouse derived human chimeric antibodies for the human CD161 protein extracellular domain (ECD) by ELISA;
[0045] Figure 7 provides binding data for mouse derived human chimeric antibodies for the cyno CD161 protein ECD by ELISA;
[0046] Figures 8 to 12 provide binding data for rabbit derived human chimeric antibodies for the human CD161 protein ECD by ELISA;
[0047] Figures 13 to 17 provide binding data for rabbit derived human chimeric antibodies for the cyno CD161 protein ECD by ELISA;
[0048] Figure 18 provides cell-surface binding data for mouse and rabbit derived human chimeric antibodies with HEK293 cells expressing human CD161;
[0049] Figure 19 provides data from a CLEC2D ligand competition assay for mouse and rabbit derived human chimeric antibodies;
[0050] Figure 20 provides CD161+ cell depletion data for increasing concentrations of mouse and rabbit human chimeric derived antibodies;
[0051] Figure 21 provides data showing depletion of CD161+ defined immune subsets as quantified by flow cytometry;
[0052] Figure 22 provides ADCC / ADCP assays in MAIT cells, reported as % depletion;
[0053] Figure 24 provides evaluation of target binding of R145 and humanized versions using HEK293F-CD161 expressing cells were stained with varying concentrations of antibody and evaluated using flow cytometry;
[0054] Figure 25 provides on-cell CD161 affinity (as geometric mean fluorescence) and CD161 affinity relative to depletion potential in ADCC / ADCP assays;
[0055] Figure 26 provides histograms showing binding competition of anti-CD161 antibodies using HEK cells overexpressing human CD161;Figure 27 provides a sequence alignment of the variable regions of humanized antibodies as described herein, including CDRs in both Kabat and IMGT.
[0056] DETAILED DESCRIPTION
[0057] According to a first aspect of the present invention, there is provided an antibody molecule or antigen binding fragment which binds to and depletes CD161+ cells and which does not significantly inhibit CD161-CLEC2D binding. The antibody molecules or antigen binding fragments of the invention specifically bind to CD161.
[0058] One of the main concerns with cell depletion therapies in the treatment or prevention of IMIDs is that the depletion of an entire cell population will have a disproportionately strong immunosuppressive effect, i.e. the subject's immune system will be excessively weakened, exposing them to risks of serious diseases such as infections and cancers. Identifying cell depletion therapies which balance the reduction in proinflammatory signalling to a level which is effective to treat, prevent and / or potentially cure IMIDs while maintaining an effective immune system has been and continues to be a serious issue facing the pharmaceutical sector.
[0059] However, as is demonstrated in the accompanying examples, the present inventors have identified that the selective targeting of CD161+ positive cells surprisingly and effectively strike this balance. The in vivo data in the examples show that on the one hand, the depletion of CD161+ cells results in a reduction of the production of proinflammatory cytokines implicated in IMIDs, while on the other hand, this is not accompanied by a significant reduction in cells required for the function of an effective immune system.
[0060] In addition, as is also demonstrated in the accompanying examples, the present inventors have also surprisingly found that by using an antibody that does not compete with the natural CD161 ligand, CLEC2D, the interaction between CD161 and CLEC2D is not significantly inhibited, minimising the risk of T cell augmentation, in contrast to anti-CD161 antibodies known in the art.
[0061] The term "deplete" as used herein refers to a partial or total reduction in the population size of viable CD161 positive cells. The population of CD161+ cells which is depleted may be present in a subject, for example in an organ, in a gland, in a tissue, in a fluid, etc, in the subject. For example, depletion can refer to the reduction in the number of viable CD161+ cells such that the number of CD161+ cells present in a subject following administration of the antibodies, antigen binding fragments or compositions according to the present invention is less than prior to such administration. Those skilled in the art will be familiarwith techniques for quantifying CD161+ cell populations in subjects (or in samples obtained from such subjects) and the examples which follow provide additional guidance on this point. Depletion can include killing, inactivating and / or disabling CD161+ cells.
[0062] As used herein, references to antibodies or antigen binding fragments which do "not significantly inhibit CD161-CLEC2D binding" refers to antibodies or antigen binding fragments that bind to CD161 in a manner that does not fully inhibit the interaction between CD161 and CLEC2D. Preferably, in the presence of the antibodies or antigen binding fragments of the present invention, the binding of CLEC2D to CD161 is not reduced or is only partially reduced compared to the binding of CLEC2D to CD161 in the absence of the said antibodies or antigen binding fragments. For example, the binding of CLEC2D to CD161 is reduced by less than 20%, less than 15%, less than 10% or less than 5% compared to the binding of CLEC2D to CD161 in the absence of the said antibodies or antigen binding fragments as measured by a maximal inhibition (Imax) assay at an antibody concentration of lpg / ml.
[0063] Regarding antibodies or antigen binding fragments which do "not significantly inhibit CD161-CLEC2D binding", the interaction between CD161 and the antibody or the antigen binding fragment may be "noncompetitive" or "partially competitive" with respect to CD161-CLEC2D binding. The term "noncompetitive" as used in this context may refer to antibodies or antigen binding fragments that bind a different CD161 epitope to CLEC2D. When bound to CD161, these antibodies or antigen binding fragments may not sterically obstruct the CD161 epitope bound by CLEC2D and hence do not reduce CLEC2D binding to CD161. As used herein, the term "partially competitive" may refer to antibodies or antigen binding fragments that that bind to a CD161 epitope which overlaps with the CD161 epitope bound by CLEC2D. When bound to CD161, these antibodies or antigen binding fragments may partially sterically obstruct the CD161 epitope bound by CLEC2D. This may lead to some degree of competition but, in the context of the antibodies or antigen binding fragments of the present invention, will still allow significant levels of CLEC2D binding. In some embodiments, the antibodies or antigen binding fragments do not compete for binding with the antibody KW1.3.12 disclosed in W02021 / 080682 and having the VH sequence of SEQ ID NO. 257 and the VL sequence of SEQ ID NO. 258.
[0064] The degree to which the antibody or antigen binding fragment inhibits CD161-CLEC2D binding can be quantified via a determination of the amount of the antibody or antigen binding fragment of the invention needed to inhibit 50% of CD161-CLEC2D binding (the Inhibitory Concentration 50% ( IC5o)) in a competition assay. In embodiments of the invention, the IC5o for the antibody or antigen binding fragment is at least about 200 ng / ml, at least about 500 ng / ml, at least about 1000 ng / ml, at least about 2000 ng / ml, at least about 5000 ng / ml or at least about 10,000 ng / ml.In some embodiments, the antibody or antigen binding fragment has an Inhibitory Concentration 50% (IC5o) of at least about 200 ng / ml, at least about 500 ng / ml, at least about 1000 ng / ml, at least about 2000 ng / ml, at least about 5000 ng / ml or at least about 10,000 ng / ml. In embodiments, the antibody or antigen binding fragment has an IC5oof at least about 1000 ng / ml, at least about 2000 ng / ml, at least about 3000 ng / ml, at least about 4000 ng / ml, at least about 5000 ng / ml, at least about 6000 ng / ml, at least about 7000 ng / ml, at least about 8000 ng / ml, at least about 9000 ng / ml, at least about 10,000 ng / ml. In embodiments, the antibody or antigen binding fragment has an IC5o of at least about 10,000 ng / ml, at least about 20,000 ng / ml, at least about 30,000 ng / ml, at least about 40,000 ng / ml, at least about 50,000 ng / ml. Preferably, the antibody or antigen binding fragment has an Inhibitory Concentration 50% (IC50) of at least about 5000 ng / ml. Even more preferably, the antibody or antigen binding fragment has an Inhibitory Concentration 50% (IC50) of at least about or at least about 10,000 ng / ml.
[0065] Assessments of IC50 in a CLEC2D-CD161 competition assay can be conducted using the methodology detailed in Example 6 below.
[0066] The antibody or antigen binding fragment of the invention specifically and functionally binds to CD161 and also does not significantly inhibit CD161-CLEC2D binding. Therefore, in some embodiments the antibody or antigen binding fragment of the invention has an Inhibitory Concentration 50% (IC50) for CLEC2D-CD161 inhibition of at least about 200 ng / ml, at least about 500 ng / ml, at least about 1000 ng / ml, at least about 2000 ng / ml, at least about 5000 ng / ml or at least about 10,000 ng / ml and an on-cell binding affinity (Kd) for CD161 of less than about 20nm, or less than about lOnm, or less than about 6nm. In some embodiments the antibody or antigen binding fragment of the invention has an Inhibitory Concentration 50% (IC50) for CLEC2D-CD161 inhibition of at least about 5000 ng / ml and an on-cell binding affinity (Kd) for CD161 of less than about lOnm. In some embodiments the antibody or antigen binding fragment of the invention has an Inhibitory Concentration 50% (IC50) CLEC2D-CD161 inhibition of at least about 10,000 ng / ml and an on-cell binding affinity (Kd) for CD161 of less than about 6nm. IC50 and on-cell binding affinity (Kd) can be measured in any suitable assay, for example those set out in Example 6 and Example 12 below.
[0067] In some embodiments, the antibody or antigen binding fragment of the invention inhibits CD161-CLEC2D binding by a lesser degree than a comparator anti CD161+ antibody, e.g. it has an IC50 in a CLEC2D-CD161 competition assay which is greater than a comparator anti CD161+ antibody. In certain embodiments, the antibody or antigen binding fragment of the invention has an IC50 in a CLEC2D-CD161 competition assay which is at least about 1.5x higher, at least about 2x higher, at least about 3x higher, at least about 4x higher, at least about 5x higher or at least about lOx higher than a comparator anti CD161+ antibody.In some embodiments, the comparator antibody is that identified as KW1.3.12 in W02021 / 080682 and has the VH sequence of SEQ. ID NO. 257 and the VL sequence of SEQ ID NO. 258.
[0068] Maximal inhibition (Imax) can also be used to determine the greatest degree of CD161-CLEC2D inhibition that can be achieved by a particular antibody, even at saturation concentrations. Imax is measured as a fraction or percentage of the baseline response. For example, an antibody with an Imax of 100% means it the antibody can completely (100%) inhibit the baseline binding of CLEC2D and CD161 (as measured without any inhibitor present). An antibody with an Imax of 10% means that antibody is only able to inhibit 10% of the baseline CD161-CLEC2D binding activity (as measured without any inhibitor present). In some embodiments, the antibody or antigen binding fragment has an Imax for CD161-CLEC2D inhibition of less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 15%, or preferably less than about 10% of the baseline CD161-CLEC2D binding activity (as measured without any inhibitor present and at an antibody concentration of lpg / ml). In some embodiments, the antibody or antigen binding fragment has an Imax for CD161-CLEC2D inhibition of less than about 10% of the baseline CD161-CLEC2D binding activity (as measured without any inhibitor present and at an antibody concentration of lpg / ml) and specifically binds to CD161 and depletes CD161+ cells. Assessments of Imax in a CLEC2D-CD161 competition assay can be conducted using the methodology detailed in Example 6 below.
[0069] In some embodiments, the antibody or antigen binding fragment has an Imax for CD161-CLEC2D inhibition of less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 15%, or preferably less than about 10% of the baseline CD161-CLEC2D binding activity (as measured without any inhibitor present and at an antibody concentration of lpg / ml) and an on-cell binding affinity (Kd) for CD161 of less than about 20nm, or less than about lOnm, or less than about 6nm. In some embodiments, the antibody or antigen binding fragment has an Imax for CD161-CLEC2D inhibition of less than about 10% of the baseline CD161-CLEC2D binding activity (as measured without any inhibitor present and at an antibody concentration of lpg / ml) and an on-cell binding affinity (Kd) for CD161 of less than about lOnm or less than about 6nm. Imax and on-cell binding affinity (Kd) can be measured in any suitable assay, for example those set out in Example 6 and Example 12 below.
[0070] As the antibodies and antigen binding fragments of the present invention bind specifically to CD161+ cells, they do not deplete CD161- subsets of immune cells and also do not substantially deplete subsets of CD161+ cells for which CD161 expression is modest, and thus avoid issues observed with immunosuppressive therapies in the prior art.
[0071] CD161 targeting antibodies have been previously disclosed in the scientific literature, for example, in International Patent Publication Nos. W02021 / 080682, W02023 / 028501 and WO2024 / 091919. Theantibodies described in those documents were selected based on potent inhibition of CD161 interacting with CLEC2D, rather than for optimal depletive potential. Consequently, they differ functionally from the antibodies and antigen binding fragments of the present invention, rendering them sub-optimal for use in the treatment and prevention of IMIDs.
[0072] More specifically, as described herein, the interaction between CD161 and its natural ligand, CLEC2D, is known to inhibit T cell activation. The antibodies of W02021 / 080682, W02023 / 028501 and WO2024 / 091919 bind CD161 epitopes that are crucial for ligand (CLEC2D) binding, thereby competing with CLEC2D. Hence, these antibodies block CLEC2D from binding CD161, preventing CLEC2D from suppressing T cell activation. As a result, sub-optimal depletion of target CD161+ cells using such antibodies could have an immune enhancing effect which is undesirable in the treatment or prevention of IMIDs where upregulation of the immune system may exacerbate the patient's condition.
[0073] In contrast, the antibodies and antigen binding fragments of the present invention do not inhibit the interaction between CLEC2D and CD161, substantially or at all. This means that CLEC2D is still able to bind to CD161 and inhibit T cell activation in the presence of the antibodies and antigen binding fragments of the present invention, contributing to an immune-damping effect.
[0074] Hence, the immunomodulatory effects elicited by the prior art antibodies are markedly different to those of the present invention, which do not bind epitopes that compete with ligand binding and thus do not augment T cell activation.
[0075] Accordingly, the present inventors specifically developed antibodies that 1) do not complete with ligand (CD161 - CLEC2D) binding, and 2) demonstrate potent depletion of CD161+ cells.
[0076] In embodiments of the invention, the antibodies or antigen binding fragments of the invention deplete a population of CD161+ cells.
[0077] In some embodiments, the antibody or antigen binding fragment depletes at least about 35%, at least about 40%, at least about 45%, at least about 50% or at least about 55% of a population of CD161+ cells in a sample.
[0078] In certain embodiments, the antibody or antigen binding fragment of the present invention depletes all of a population of CD161+ cells in a sample. In some embodiments, the antibody or antigen binding fragment of depletes at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 99% of a population of CD161+ cells in a sample.In embodiments of the invention, the population of CD161+ cells which are depleted by the antibodies and antigen-binding fragments of the invention comprise mucosal-associated invariant T (MAIT) cells. In embodiments of the invention, the population of CD161+ cells which are depleted by the antibodies and antigen-binding fragments of the invention are mucosal-associated invariant T (MAIT) cells.
[0079] In embodiments of the invention, the population of CD161+ cells which are depleted by the antibodies and antigen-binding fragments of the invention comprise Type 3 Innate Lymphoid cells (ILC3) cells. In embodiments of the invention, the population of CD161+ cells which are depleted by the antibodies and antigen-binding fragments of the invention are Type 3 Innate Lymphoid cells (ILC3) cells.
[0080] In embodiments of the invention, the CD161+ cells which are depleted by the antibodies and antigen binding fragments of the invention produce pro-inflammatory molecules such as cytokines, chemokines and / or proteases. In embodiments of the invention, the population of CD161+ cells which are depleted by the antibodies and antigen binding fragments of the invention produce at least one pro-inflammatory cytokine. Examples of pro-inflammatory cytokines are selected from the group consisting of IL-17 (A / F), IL-23, IL-22, IFNy, IL-26, TNFa, IL-2, IL-21 and GM-CSF. The depletion of CD161+ cells which produce IL-17, for example IL-17A and / or IL-17F are particularly preferred.
[0081] In embodiments of the invention, the population of CD161+ cells which are depleted by the antibodies and antigen binding fragments of the invention produce at least one chemokine selected from the group consisting of CSF2, CCL20, CXCL13. In embodiments of the invention, the CD161+ cells which are depleted by the antibodies and antigen binding fragments of the invention do not produce CCL3. In embodiments of the invention, the CD161+ cells which are depleted by the antibodies and antigen binding fragments of the invention produce at least one protease such as GZMB. In some embodiments, the CD161+ cells which are depleted by the antibodies and antigen binding fragments of the invention do not produce at least one protease GZMB.
[0082] As used herein, the term "selectivity" in the context of CD161+ cell depletion means that the administration of the antibody, antigen binding fragment or other therapeutic discussed herein results in a reduction in a first population of CD161+ cells without this being accompanied by a reduction of corresponding magnitude in other cell populations, e.g. a second population of CD161+ cells. In some embodiments, the second population of CD161+ cells are NK cells. In some embodiments, the second population of CD161+ cells are NKT cells. In certain embodiments, the second population of CD161+ cells comprise NK and NKT cells. In some embodiments, the second population of CD161+ cells consist of NK and NKT cells.In embodiments, in a given tissue or fluid sample, the proportional reduction in the size of a second population of CD161+ cells (e.g. NK and / or NKT cells) may be at least about 75% or less, about 50% or less, about 40% or less, about 30% or less, about 20% or less or about 10% or less of the proportional reduction in the population of the first population of CD161+ cells (e.g. MAIT cells). By way of example, if administration of the antibody, antigen binding fragment or other therapeutic resulted in an 80% reduction in the size of the first population of CD161+ cells (e.g. MAIT cells) and a 40% reduction in the second population of CD161+ cells (e.g. NK cells), the reduction in the size of the second population of CD161+ cells (e.g. NK and / or NKT cells) would be 50% of the reduction in the first population of CD161+ cells (e.g. MAIT cells).
[0083] The term "antibody molecule" or "antibody" is used herein in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multi-specific antibodies (e.g. bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding and selective cell depleting activity.
[0084] The term "antigen binding fragment" or "antigen-binding region" of an antibody, as used herein, refers to that region or fragment of the antibody that binds to the antigen and which confers antigen specificity to the antibody; fragments of antigen-binding proteins. For example, the term 'antibody' includes one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., a CD161 polypeptide or a part thereof). Examples of antigen-binding fragments encompassed within the term "antibody fragments" of an antibody include a Fab fragment, a monovalent fragment consisting of the VL , VH , CL and CHI domains; a F(ab)z fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; a Fd fragment consisting of the VH and CHI domains; a Fv fragment consisting of the VL and VH domains of a single arm of an antibody; a dAb fragment (Ward et al., Nature 1989;341:544-546), which consists of a VH domain; and an isolated complementarity determining region (CDR).
[0085] The term "CD161 positive cells" indicates one or more cells that express CD161 as a surface marker. The terms "CD161 positive" and "CD161+" are used interchangeably in the present disclosure.
[0086] The antibody or antigen binding fragment may deplete the CD161 positive cells by any suitable means known in the art. For example, in embodiments, depletion of CD161+ cells may occur as a direct result of the antibody molecule or antigen binding fragment binding to CD161. For example, in embodiments, the binding of the antibody molecule or antigen binding fragment to CD161 depletes the CD161 bearing cell by inducing apoptosis therein.In addition, or alternatively, depletion of CD161+ cells may occur as an indirect result of the antibody molecule or antigen binding fragment binding to CD161. For example, in embodiments, the antibody molecule or antigen binding fragment may deplete a cell upon contact with CD161 through the antibody's interaction with other immune cells or molecules. For example, in embodiments, binding of the antibody molecule or antigen binding fragment to CD161 may trigger immune effector signalling cascades such as antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and / or antibody mediated phagocytosis (ADCP).
[0087] In embodiments, the antibody or antigen binding fragment may be mutated to confer increased affinity, avidity, and / or anti-pathogen activity. Techniques for mutation are well known in the art and include antibody affinity maturation. Antibody affinity maturation is a process by which antibodies gain increased affinity, avidity, and anti-pathogen activity. Standard antibody affinity maturation techniques include two mutagenesis strategies: stochastic and targeted mutagenesis. In stochastic mutagenesis, the sequences for the variable fragment can be mutated randomly through error-prone PCR or by introducing mutator bacterial strains. Targeted mutagenesis introduces mutations in predictable positions, in selected CDR and framework regions, and are also workable by window mutagenesis or site-directed mutagenesis.
[0088] In embodiments, the antibody or antigen binding fragment of the invention is specifically modified or mutated to increase its ability to selectively deplete CD161+ cells. For example, the Fc region of the antibody or antigen binding fragment may be mutated to increase or decrease its affinity for target FcRs and / or complement components.
[0089] The term "Fc region" as used herein refers to the fragment crystallizable region of the antibody or antigen binding fragment, namely the C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In embodiments, the Fc region is a human IgGl, lgG2, lgG3, or lgG4 Fc region. In preferred embodiments, the Fc region is a human IgGl Fc region.
[0090] In embodiments, the Fc region binds at least one FcR and / or complement component. Exemplary FcRs bound by the Fc region include, but are not limited to, Fc-gamma Receptors (FcyRs), Fc-epsilon Receptors (FceRs), the Fc-alpha Receptors (FcaR) and Neonatal Fc Receptors (FcRn). Exemplary complement components bound by the Fc region include, but are not limited to lq (Clq), 4b (C4b) and 3b (C3b).
[0091] Antibody SequencesAs mentioned above, CD161 targeting antibodies have been disclosed in the literature, for example in International Patent Publication Nos. WO 2021 / 080682 A2, W02023 / 028501 Al and WO 2024 / 091919 A2, the contents of which are incorporated herein by reference. However, there has been no disclosure in the art of CD161+ targeting antibodies which selectively deplete CD161+ cells and which do not substantially compete with the CD161 natural ligand, CLEC2D, nor the use of these antibodies in treating or preventing IMIDs.
[0092] Thus, in some embodiments, the antibody molecule or antigen binding fragment of the present invention may comprise:
[0093] i) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 1, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 2 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 3, and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 4, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 5 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 6; or
[0094] ii) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 7, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 8 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 9, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 10, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 11 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 12;
[0095] iii) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 13, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 14, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 15 and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 16, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 17 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 18; oriv) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 19, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 20 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 21, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 22, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 23 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 24;
[0096] v) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 25, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 26 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 27, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 28, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 29, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 30;
[0097] vi) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 31, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 32 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 33, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 34, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 35, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 36; or
[0098] vii) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 37, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 38 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 39, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 40, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 41, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 42; orviii) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 43, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 44, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 45, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 46, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 47, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 48; or
[0099] ix) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 49, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 50 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 51, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 52, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 53, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 54; or
[0100] x) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 55, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 56 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 57, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 58, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 59, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 60; or
[0101] xi) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 61, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 62, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 63, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 64, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 65, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 66; orxii) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 348 (IMGT), a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 349 (IMGT), and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 350 (IMGT), and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 351 (IMGT), a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 352 (IMGT), and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 353 (IMGT); or
[0102] xiii) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 67, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 68 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 69, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 70, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 71, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 72; or
[0103] xiv) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 73, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 74 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 75, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence SEQ ID NO. 76, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 77, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 78; or
[0104] xv) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 79, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 80 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 81, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 82, a light chain complementarity determining region 2 (VLCDR2)amino acid sequence of SEQ ID NO. 83, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 84; or
[0105] xvi) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 85, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 86, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 87 and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 88, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 89 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 90; or
[0106] xvii) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 260, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 261, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 262 and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 263, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 264 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 265; or
[0107] xviii) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 266, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 267, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 268 and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 269, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 270 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 271; or
[0108] xix) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 276, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. Til and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 278, and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 279, a light chain complementarity determiningregion 2 (VLCDR2) amino acid sequence of SEQ ID NO. 280 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 281; or
[0109] xx) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 282, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 283 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 284, and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 285, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 286 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 287; or
[0110] xxi) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 288, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 289 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 290, and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 291, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 292 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 293; or
[0111] xxii) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 294, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 295 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 296, and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 297, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 298 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 299; or
[0112] xxiii) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 300, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence ofSEQ ID NO. 301 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 302, and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 303, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 304 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 305; or
[0113] xxiv) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 306, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 307 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 308, and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 309, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 310 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 311; or
[0114] xxv) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 312, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 313 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 314, and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 315, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 316 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 317; or
[0115] xxvi) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 318, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 319 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 320, and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 321, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 322 and a light chaincomplementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 323; or
[0116] xxvii) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 324, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 325 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 326, and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 327, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 328 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 329; or
[0117] xxviii) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 61, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 354 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 63, and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 355, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 65 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 66; or
[0118] xxix) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 348 (IMGT), a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 356 (IMGT) and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 350 (IMGT), and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 351 (IMGT), a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 352 (IMGT) and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 353 (IMGT).
[0119] In preferred embodiments, the antibody molecule or antigen binding fragment comprises:
[0120] i) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 1,a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 2 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 3, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 4, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 5 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 6; or
[0121] ii) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 266, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 267, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 268 and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 269, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 270 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 271; or
[0122] iii) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 61, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 62, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 63, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 64, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 65, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 66;
[0123] iv) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 348 (IMGT), a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 349 (IMGT), and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 350 (IMGT), and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 351 (IMGT), a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 352 (IMGT), and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 353 (IMGT); orv) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 67, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 68 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 69, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 70, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 71, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 72;
[0124] vi) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 260, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 261, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 262 and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 263, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 264 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 265; or
[0125] vii) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 25, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 26 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 27, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 28, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 29, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 30;
[0126] viii) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 37, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 38 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 39, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 40, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 41, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 42; orix) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 73, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 74 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 75, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence SEQ ID NO. 76, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 77, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 78; or
[0127] x) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 61, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 354 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 63, and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 355, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 65 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 66; or
[0128] xi) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 348 (IMGT), a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 356 (IMGT) and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 350 (IMGT), and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 351 (IMGT), a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 352 (IMGT) and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 353 (IMGT).
[0129] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 1, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 2 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 3, and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 4, a light chain complementaritydetermining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 5 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 6.
[0130] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 7 , a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 8 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 9, and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 10, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 11 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 12.
[0131] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 13, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 14, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 15 and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 16, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 17 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 18.
[0132] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 19, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 20 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 21, and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 22, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 23 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 24.
[0133] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 25, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 26 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 27, and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 28, a light chain
[0134] 1complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 29, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 30.
[0135] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 31, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 32 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 33, and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 34, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 35, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 36.
[0136] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 37, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 38 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 39, and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 40, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 41, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 42.
[0137] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 43, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 44, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 45, and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 46, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 47, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 48.
[0138] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 49, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 50 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 51, and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 52, a light chaincomplementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 53, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 54.
[0139] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 55, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 56 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 57, and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 58, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 59, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 60.
[0140] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 61, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 62, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 63, and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 64, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 65, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 66.
[0141] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 348 (IMGT), a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 349 (IMGT), and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 350 (IMGT), and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 351 (IMGT), a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO.
[0142] 352 (IMGT), and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 353 (IMGT).
[0143] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 67, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 68 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 69, and a light chain variable region (VL) comprising a light chaincomplementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 70, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 71, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 72.
[0144] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 73, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 74 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 75, and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence SEQ ID NO. 76, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 77, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 78.
[0145] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 79, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 80 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 81, and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 82, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 83, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 84.
[0146] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 85, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 86, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 87 and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 88, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 89 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 90.
[0147] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 260, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 261, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 262 and a light chain variable region (VL) comprising a light chaincomplementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 263, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 264 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 265.
[0148] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 266, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 267, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 268 and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 269, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 270 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 271.
[0149] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 276, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 277 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 278, and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 279, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 280 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 281.
[0150] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 282, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 283 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 284, and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 285, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 286 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 287.
[0151] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 288, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 289 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 290, and a light chain variable region (VL) comprising a light chaincomplementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 291, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 292 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 293.
[0152] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 294, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 295 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 296, and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 297, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 298 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 299.
[0153] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 300, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 301 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 302, and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 303, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 304 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 305.
[0154] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 306, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 307 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 308, and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 309, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 310 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 311.
[0155] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 312, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 313 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 314, and a light chain variable region (VL) comprising a light chaincomplementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 315, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 316 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 317.
[0156] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 318, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 319 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 320, and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 321, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 322 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 323.
[0157] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 324, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 325 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 326, and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 327, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 328 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 329.
[0158] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 61, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 354 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 63, and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 355, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 65 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 66.
[0159] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 348 (IMGT), a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 356 (IMGT) and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 350 (IMGT), and a light chain variable region (VL) comprisinga light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 351 (IMGT), a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO.
[0160] 352 (IMGT) and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 353 (IMGT).
[0161] In some embodiments, the antibody molecule or antigen binding fragment of the present invention may comprise:
[0162] i) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 91 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 92; or
[0163] ii) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 93 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 94; or
[0164] iii) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 95 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 96; or
[0165] iv) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 97 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 98; or
[0166] v) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 99 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 100; or
[0167] vi) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 101 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 102; or
[0168] vii) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 103 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 104; or
[0169] viii) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 105 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 106; or
[0170] ix) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 107 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 108; orx) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 109 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 110; or
[0171] xi) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. Ill and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 112; or
[0172] xii) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 113 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 114; or
[0173] xiii) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 115 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 116; or
[0174] xiv) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 117 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 118; or
[0175] xv) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 119 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 120; or
[0176] xvi) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 272 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 273; or
[0177] xvii) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 274 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 275; xviii) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 330 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 331; or
[0178] xix) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 332 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 333; or
[0179] xx) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 334 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 335; or
[0180] xxi) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 336 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 337; orxxii) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 338 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 339; or
[0181] xxiii) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 340 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 341; or
[0182] xxiv) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 342 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 343; or
[0183] xxv) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 344 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 345; or
[0184] xxvi) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 346 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 347; xxvii) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 357 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO.
[0185] 359; or
[0186] xxviii) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 357 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO.
[0187] 360; or
[0188] xxix) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 357 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO.
[0189] 361; or
[0190] xxx) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 357 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO.
[0191] 362; or
[0192] xxxi) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 358 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO.
[0193] 359; or
[0194] xxxii) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 358 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO.
[0195] 360; or
[0196] xxxiii) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 358 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO.xxxiv) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 358 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 362.
[0197] In preferred embodiments, the antibody molecule or antigen binding comprises:
[0198] i) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 91 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 92; or
[0199] ii) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 274 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 275;
[0200] iii) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. Ill and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 112; or
[0201] iv) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 113 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 114; or
[0202] v) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 272 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 273; or
[0203] vi) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 99 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 100; or
[0204] vii) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 103 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 104; or
[0205] viii) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 115 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 116.
[0206] In preferred embodiments, the antibody molecule or antigen binding fragment thereof is a humanized antibody or antigen binding fragment thereof and comprises:
[0207] i) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 357 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 359; orii) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 357 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 360; or
[0208] iii) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 357 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 361; or
[0209] iv) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 357 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 362; or
[0210] v) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 358 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 359; or
[0211] vi) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 358 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 360; or
[0212] vii) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 358 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 361; or
[0213] viii) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 358 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 362.
[0214] In some embodiments, the antibody or antigen-binding fragment may comprise a heavy chain variable region (VH) comprising an amino acid sequence which has at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98% or at least about 99% identity to SEQ ID NOS. 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 272, 274, 330, 332, 334, 336, 338, 340, 342, 344,346, 357 or 358.
[0215] In some embodiments, the antibody or antigen-binding fragment may comprise a heavy chain variable region (VH) comprising an amino acid sequence which has at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98% or at least about 99% identity to SEQ ID NOS. 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 272,274, 359, 360, 361In some embodiments, the antibody or antigen-binding fragment may comprise a heavy chain variable region (VH) comprising an amino acid sequence which has at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98% or at least about 99% identity to SEQ ID NOS 91, 99, 103, 111, 113, 115, 272, 274, 357 or 358.
[0216] In some embodiments, the antibody or antigen-binding fragment may comprise a light chain variable region (VL) comprising an amino acid sequence which has at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98% or at least about 99% identity to SEQ ID NOS. 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 273, 275, 331. 333. 335.
[0217] 337. 339, 341, 343, 345,347, 359, 360, 361 or 362.
[0218] In some embodiments, the antibody or antigen-binding fragment may comprise a light chain variable region (VL) comprising an amino acid sequence which has at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98% or at least about 99% identity to SEQ ID NOS. 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 273, 275, 359, 360, 361 or 362.
[0219] In some embodiments, the antibody or antigen-binding fragment may comprise a light chain variable region (VL) comprising an amino acid sequence which has at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98% or at least about 99% identity to SEQ ID NOS. 92, 100, 104, 112, 114, 116, 273, 275, 359, 360, 361 or 362.
[0220] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 91 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 92.
[0221] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 93 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 94.
[0222] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 95 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 96.In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 97 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 98.
[0223] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 99 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 100.
[0224] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 101 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 102.
[0225] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 103 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 104.
[0226] In embodiments, the antibody molecule or antigen binding fragment comprises heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 105 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 106.
[0227] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 107 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 108.
[0228] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 109 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 110.
[0229] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. Ill and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 112.
[0230] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 113 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 114.In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 115 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 116.
[0231] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 117 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 118.
[0232] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 119 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 120.
[0233] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 272 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 273.
[0234] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 274 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 275.
[0235] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 330 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 331.
[0236] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 332and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 333.
[0237] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 334 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 335.
[0238] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 336 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 337.In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 338 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 339.
[0239] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 340 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 341.
[0240] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 342 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 343.
[0241] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 344 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 345.
[0242] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 346 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 347.
[0243] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 357 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 359.
[0244] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 357 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 360.
[0245] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 357 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 361.
[0246] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 357 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 362.In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 358 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 359.
[0247] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 358 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 360.
[0248] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 358 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 361.
[0249] In embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 358 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 362. Each of the VH and VL pairings disclosed herein may suitably be combined with any heavy chain constant region and a light chain constant region disclosed herein.
[0250] As used herein, the term "variable region" or "variable domain" refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen. The variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs or CDRs). (See, e.g., Kindt et al. Kuby Immunology, 6th ed., W.H. Freeman and Co., page 91 (2007). A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al., J. Immunol.
[0251] 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991).
[0252] In embodiments, a presently disclosed antibody or antigen binding fragment comprises heavy and light chain variable regions comprising amino acid sequences that are homologous or identical to the amino acid sequences of the antibodies described herein, and wherein the antibodies or antigen binding fragments retain the desired functional properties of the anti-CD161 antibodies or antigen-binding fragments of the presently disclosed subject matter.
[0253] In certain embodiments, the VHCDR1, VHCDR2 and / or VHCDR3 amino acid sequences can be at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%,about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% homologous or identical to the sequences set forth herein.
[0254] In certain embodiments, the VLCDR1, VLCDR2 and / or VLCDR3 amino acid sequences can be at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% homologous or identical to the sequences set forth herein.
[0255] In certain embodiments, the VH and / or VL amino acid sequences can be at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% homologous or identical to the sequences set forth herein.
[0256] An antibody or antigen binding fragment having VHCDR1, VHCDR2 and / or VHCDR3 amino acid sequences having high (i.e., 80% or greater) homology or identity to the VHCDR1, VHCDR2 and / or VHCDR3 amino acid sequences set forth above, can be obtained by mutagenesis (e.g., site- directed or PCR-mediated mutagenesis), followed by testing of the encoded altered antibody for retained function (i.e., the binding affinity) using the binding assays described herein.
[0257] An antibody or antigen binding fragment having VLCDR1, VLCDR2 and / or VLCDR3 amino acid sequences having high (i.e., 80% or greater) homology or identity to the VHCDR1, VHCDR2 and / or VHCDR3 amino acid sequences set forth above, can be obtained by mutagenesis (e.g., site- directed or PCR-mediated mutagenesis), followed by testing of the encoded altered antibody for retained function (i.e., the binding affinity) using the binding assays described herein.
[0258] As used herein, the percent homology between two amino acid sequences is equivalent to the percent identity between the two sequences. The percent identity or homology between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % homology = # of identical positions / total # of positions x 100), taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm, as described in the non-limiting examples below.
[0259] The percent homology or identity between two amino acid sequences can be determined using the algorithm of E. Meyers and W. Miller (Comput Appl Biosci (1988);14: 11-17) which has been incorporated into the ALIGN program (version 2.0), using a P AMI 20 weight residue table, a gap length penalty of 12and a gap penalty of 4. In addition, the percent homology between two amino acid sequences can be determined using the Needleman and Wunsch (J Mol Biol (1970);48:444-453) algorithm which has been incorporated into the GAP program in the GCG software package (available at www.gcg.com), using either a Blossum 62 matrix or a PAM 250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.
[0260] In addition, or alternatively, the antibody or antigen binding fragment may comprise at least one functionally equivalent residue to at least one amino acid sequence set forth above.
[0261] A "functionally equivalent residue" of an amino acid used herein typically refers to other amino acid residues having physiochemical and stereochemical characteristics substantially similar to the original amino acid. The physiochemical properties include water solubility (hydrophobicity or hydrophilicity), dielectric and electrochemical properties, physiological pH, partial charge of side chains (positive, negative or neutral) and other properties identifiable to a person skilled in the art. The stereochemical characteristics include spatial and conformational arrangement of the amino acids and their chirality. For example, glutamic acid is considered to be a functionally equivalent residue to aspartic acid in the sense of the current disclosure. Tyrosine and tryptophan are considered as functionally equivalent residues to phenylalanine. Arginine is considered to be a functionally equivalent residue to lysine.
[0262] In addition or alternatively, a sequence disclosed herein, e.g., a CDR sequence, a VH sequence or a VL sequence, can have up to about one, up to about two, up to about three, up to about four, up to about five, up to about six, up to about seven, up to about eight, up to about nine or up to about ten amino acid residues that are modified and / or substituted.
[0263] In embodiment, the substitutions comprise at least one conservative amino acid substitutions. "Conservative" amino acid substitutions are ones in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. Amino acid substitutions may be introduced into an antibody of interest and the products screened for a desired activity, e.g., retained / improved antigen binding, decreased immunogenicity, or improved, reduced or abolished ADCC or CDC.
[0264] In addition, or alternatively, the protein sequences of the presently disclosed subject matter can further be used as a "query sequence" to perform a search against public databases to, for example, identify related sequences. Such searches can be performed using the XBLAST program (version 2.0) of Altschul et al., J Mol Biol (1990):215:403- 10. BLAST protein searches can be performed with the XBLAST program, score = 50, word length = 3 to obtain amino acid sequences homologous to the antibody molecules of theinvention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et ah, Nucleic Acids Res (1997);25( 17): 3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. 43.4. Antibodies with Conservative Modifications.
[0265] Modified Antibodies
[0266] Any of the antibody sequences described herein may comprise further modifications, for example to the Fab or Fc regions.
[0267] In preferred embodiments, the Fc region is afucosylated. The term "afucosylated" as used herein refers to antibody molecules or antigen binding fragments which have been engineered to remove all or some of the fucose sugar units from oligosaccharides within the Fc region. An afucosylated antibody may have been produced under conditions where natural fucosylation is inhibited or reduced significantly. Methods of Afucosylation are known in the art, for example transfecting low fucosylation cells with an expression vector that encodes the antibody of interest. Low fucosylation cells include those which comprise a modified, knocked down or knocked out fucosyltransferase enzyme such as FUT8. Afucosylation may be total (100% of the antibody molecules are afucosylated). Afucosylation may be partial with a mix of fucosylated and afucosylated antibodies (e.g. at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97, 98% or 99% of antibody molecules are afucosylated). Afucosylation increases the affinity to various FcyRs, thereby enhancing both ADCC and ADCP1. ADCC or ADCP activity can be assessed directly using an in vitro assay. In some embodiments, the ADCC activity of afucosylated antibodies described herein is at least 2, 3, 5, 10, 20, 50, or 100-fold higher than that of the wild-type (fucosylated) antibody. Thus, advantageously, afucosylation thereby increases the ability of the antibody molecule or antigen binding fragment of the invention to deplete CD161+ cells. For example, the depletion capacity of an afucosylated antibody as described herein may be at least 2, 3, 5, 10, 20, 50, or 100-fold higher than that of its wild-type (fucosylated) counterpart.
[0268] In addition, or alternatively, the Fc region may comprise at least one or, preferably, all mutations selected from G236A, S239D, A330L, and / or I332E (GASDALIE mutations). In embodiments, the Fc region may comprise the K439E mutation. The antibody molecule or antigen binding fragment may comprise a heavy chain constant region comprising the sequence of SEQ. ID NO. 376. In further preferred embodiments, the Fc region may comprise all four GASDALIE mutations and at least one of D265S and / or K439E. In addition, or alternatively, the Fc region may comprise at least one or, preferably, both mutations selected fromS239D and / or I332E (DE mutations). In further preferred embodiments, the Fc region may comprise both DE mutations and K439E. In embodiments, the Fc region is afucosylated in addition to comprising any of the GASDALIE mutations, DE mutations, and / or FTDE mutations. In further preferred embodiments, the Fc region is afucosylated and comprises K439E. In further preferred embodiments, the Fc region is afucosylated and comprises D265S. In further preferred embodiments, the Fc region is afucosylated and comprises K439E and D265S. These mutations have also been shown to increase binding affinity to FcyRllla, thereby enhancing ADCC2-3.
[0269] In addition, or alternatively, the Fc region may be galactosylated. Galactosylation may be partial or total. The term "galactosylation" as used herein refers to the addition of at least one galactose sugar to the Fc region of the antibody molecule or antigen binding fragment. Advantageously, galactosylation improves the binding of antibodies to the complement component Clq. This enhances complement-dependent cytotoxicity (CDC), thereby increasing the ability of the antibody molecule or antigen binding fragment of the invention to deplete CD161+ cells4.
[0270] In addition, or alternatively, the Fc region may comprise at least one mutation which enhances its affinity for target FcRs and / or complement components. For example, when the Fc region is a human IgGl Fc region, it may comprise at least one mutation selected from S267E, H268F and / or S324T. Advantageously, these mutations increase binding affinity to FcyRllla, thereby enhancing ADCC5.
[0271] In addition, or alternatively, when the Fc region is a human IgGl Fc region, it may comprise at least one mutation selected from E345R, E430G, and / or S440Y. Advantageously, these mutations result in the formation of IgG hexamers which enhance CDC6.
[0272] In embodiments, the Fc region is modified or mutated to reduce its affinity for FcRs and / or complement components. These mutations may be referred to as "silencing mutations". For example, in embodiments where the Fc region is a human IgGl Fc region, it comprises L234A and / or L235A mutations (LALA mutations). Advantageously, these mutations reduce binding affinity for FcyR, thereby reducing unwanted effector functions7.
[0273] https / pmc.ncbi.nlm. nih.gov / articles / PMC11418285 /
[0274] 3< M ' < I ' I '? I ' 's ' ' '? I ' (abstract)
[0275] 4https: / / pubmed.ncbi.nlm.nih.gov / 28634480 / https ' / / io u rna Is aai org / iimmunol / article / 194 / ll / 5497 / 98731 / Fc~Engineering~of-Human~lgG
[0276] 6 https: / / academic.oup.eom / proteincell / article / 9 / l / 63 / 6768230
[0277] 7https: / / www.mdpi.eom / 2073-4468 / 12 / 3 / 54
[0278]
[0279] In addition, or alternatively, the antibody molecule or antigen binding fragment may comprise an antibody-conjugate. The antibody conjugate may comprise at least the antibody molecule or antigen binding fragment of the present invention coupled to a coupling moiety.
[0280] In embodiments, the coupling moiety may couple the antibody molecule or antigen binding fragment to a cargo. In embodiments, the cargo may be a therapeutic agent, a protein, a diagnostic or detectable marker or an affinity tag.
[0281] In embodiments where the cargo is a therapeutic agent, the cargo is a drug or toxin. In embodiments, the cargo is a cytotoxic agent such as a chemotherapy drug. The drug or toxin may be delivered to the CD161+ by the antibody or antigen binding fragment to which it is coupled, depleting the CD161+ cell.
[0282] The modifications described herein can be combined with any of the antibody sequences described herein.
[0283] In embodiments there is provided an antibody molecule or antigen binding fragment comprising:
[0284] a. a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 61, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 62, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 63, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 64, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 65, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 66; and
[0285] b. an Fc region, wherein the Fc region is afucosylated and / or comprises K439E.
[0286] In embodiments there is provided an antibody molecule or antigen binding fragment comprising:
[0287] a. a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 348 (IMGT), a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 349 (IMGT), and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 350 (IMGT), and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 351 (IMGT), a light chaincomplementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 352 (IMGT), and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 353 (IMGT); and
[0288] b. an Fc region, wherein the Fc region is afucosylated and / or comprises K439E.
[0289] In preferred embodiments there is provided an antibody molecule or antigen binding fragment comprising:
[0290] a. a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 61, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 354 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 63, and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 355, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 65 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 66; and
[0291] b. an Fc region, wherein the Fc region is afucosylated and / or comprises K439E.
[0292] In preferred embodiments there is provided an antibody molecule or antigen binding fragment comprising:
[0293] a. a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 348 (IMGT), a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 356 (IMGT) and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 350 (IMGT), and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 351 (IMGT), a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 352 (IMGT) and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 353 (IMGT); and b. an Fc region, wherein the Fc region is afucosylated and / or comprises K439E.
[0294] Antibody binding
[0295] The antibody molecules and antigen binding fragments described herein are anti-CD161 antibodies, in other words, an antibody or antigen binding fragment that specifically binds to CD161. In certainembodiments, CD161 is human CD161 comprising or consisting of the amino acid sequence with a UniProt® Reference No: Q12918 or a fragment thereof.
[0296] An antibody that "specifically binds" to an antigen or an epitope (or is "specific" for an antigen or epitope) is a term well understood in the art. A molecule is said to exhibit "specific binding" if it reacts more frequently, more rapidly, with greater duration and / or with greater affinity with a particular target antigen or epitope, than it does with alternative targets. An antibody "specifically binds" to a target antigen or epitope if it binds with greater affinity, avidity, more readily, and / or with greater duration than it binds to other substances.
[0297] In certain embodiments, the CD161 comprises or consists of an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% identical to the amino acid sequence according to SEQ ID NO. 256 or a fragment thereof. The anti-CD161 antibodies or antigen-binding fragments thereof bind to a portion of human CD161.
[0298] In some embodiments, the antibody molecule of antigen binding fragment of any aspect of the invention binds to a specific epitope in the amino acid sequence according to SEQ ID NO. 256 of CD161.
[0299] In some embodiments, the antibody molecule or antigen binding fragment may bind an epitope comprising at least about 3, at least about 5, at least about 7 or at least about 10 amino acid residues. In certain embodiments, the antibody molecule or antigen binding fragment may bind an epitope comprising about 50 or fewer, about 40 or fewer, about 30 or fewer about 25 or fewer or about 20 or fewer amino acid residues. In embodiments of the invention, the antibody molecule or antigen binding fragment may bind an epitope comprising about 3 to about 50, about 50 to about 30 or about 10 to about 25 amino acid residues.
[0300] In embodiments, the antibody molecule or antibody binding fragment binds an epitope comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acid residues, or 1-3, 3-6, 6-9, 9-12, 12-15, 15-20, or 20-25 amino acid residues.
[0301] The epitope may be at least five, at least six, at least seven, at least eight, at least nine, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 25, at least 30, or at least 35 amino acids in length. The epitope may be five to 20 amino acids in length. The epitope may be five to 15 amino acids in length. The epitope may be five to 12 amino acidsin length. The epitope may be six to 12 amino acids in length. The epitope may be seven to 12 amino acids in length.
[0302] In embodiments, the antibody molecule or antibody binding fragment binds an epitope which is a nonlinear or discontinuous. A non-linear epitope may comprise a number of amino acid fragments that are not linear in sequence, but which are brought together when the protein folds. A discontinuous epitope may comprise any non-consecutive residues bound by the specific binding molecule. Discontinuous epitopes are typically formed by non-consecutive residues adopting nearby positions in three-dimensional space due to the folding of a polypeptide.
[0303] Alanine screening experiments can be used to identify specific epitope amino acid residues involved in antibody-antigen binding by substituting individual amino acids for alanine. Such methods are known in the art (see e.g., Gershoni, Jonathan M., et al. "Epitope mapping: the first step in developing epitopebased vaccines." BioDrugs 21 (2007): 145-15).
[0304] Antibody structure
[0305] The antibody molecule or antigen binding fragment may have any structure providing that it binds to and selectively depletes CD161+ positive cells without substantially competing with CLEC2D / CD161 binding. For example, in embodiments, the antibody molecule or antigen binding fragment is monoclonal or polyclonal.
[0306] The term "monoclonal" as used herein refers to an antibody or antigen binding fragment obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and / or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the presently disclosed subject matter may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phagedisplay methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein.The term "polyclonal" as used herein refers to an antibody or an antigen binding fragment obtained from a population of substantially heterogenous antibodies, i.e., the individual antibodies comprising the population are diverse and typically bind different epitopes. Thus, the modifier "polyclonal" indicates the character of the antibody as being obtained from a substantially heterogenous population of antibodies and is not to be construed as requiring production of the antibody by any particular method. For example, the polyclonal antibodies to be used in accordance with the presently disclosed subject matter may be made by a variety of techniques, including but not limited to injecting a host such as a rabbit or goat with a target antigen to elicit an immune response, and subsequently harvesting polyclonal antibodies from the host's serum.
[0307] In some embodiments, the antibody molecule or antigen binding fragment may be selected from the group consisting of a monovalent antibody, a Fab, a Fab', a F(ab')2, a single chain variable fragment (scFv), an antibody domain, a nanobody (VHH), a Shark VNAR, a minibody and an scFv-FC; and variations thereof.
[0308] As used herein, the term "monovalent antibody" refers to an antibody which has an affinity for one epitope, antigen, or strain of microorganism i.e. is an antibody fragment with one antigen-binding site.
[0309] As used herein, the term "F(ab)" refers to a fragment of an antibody structure that binds to an antigen but is monovalent and does not have a Fc portion, for example, an antibody digested by the enzyme papain yields two F(ab) fragments and an Fc region (e.g., a heavy (H) chain constant region; Fc region that does not bind to an antigen).
[0310] As used herein, the term "Fab"' refers to a fragment which is similar to a Fab fragment but includes some of the Fc portion or hinge of the antibody. Fab' fragments are formed by reducing F(ab')2 fragments and therefore contain a small portion of Fc. As opposed to F(ab) fragments, Fab' fragments contain a free sulfhydryl group that can be alkylated or used in a conjugation with another compound of interest (such as a protein, toxin or dye). As used herein, "F(ab')2 " refers to an antibody fragment generated by pepsin digestion of whole IgG antibodies, wherein this fragment has two antigen binding (a b' ) (bivalent) regions, wherein each (ab1) region comprises two separate amino acid chains, a part of a H chain and a light (L) chain linked by an S-S bond for binding an antigen and where the remaining H chain portions are linked together. A "F(ab')2 " fragment can be split into two individual Fab' fragments. As used herein, the term "vector" refers to any genetic element, such as a plasmid, phage, transposon, cosmid, chromosome, virus, virion, etc., which is capable of replication when associated with the proper control elements and which can transfer gene sequences into cells. Thus, the term includes cloning and expression vehicles, as well as viral vectors and plasmid vectors.As used herein, the term "Single-chain variable fragments" (scFv) refers to single polypeptides that contain the variable light chain (VL) and variable heavy chain (VH) of an antibody. These two chains are connected by a flexible linker peptide that is usually 15-20 amino acids long.
[0311] As used herein, the term "single-domain antibodies", also known as nanobodies, VHH or heavy-chain antibodies (hcAbs) are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain embodiments, a singledomain antibody is a human single-domain antibody (Domantis, Inc., Waltham, Mass.; see, e.g., U.S. Pat. No. 6,248,516 Bl).
[0312] As used herein, the term "Shark VNAR" refers to the isolated variable antigen receptor single domain antibody derived from naturally occurring single-chain antibodies found in sharks and has several advantages over conventional monoclonal antibodies, such as improved thermostability.
[0313] As used herein, the term "minibody" refers to a class of bispecific fragments which are scFv-derived bispecific molecules. It is a bivalent fusion molecule with two scFvs fused to CH3. The scFv targeting antigen A is fused to the N-terminus of one of the CH3 domains and the scFv targeting antigen B to the other CH3.
[0314] Fab fragments, scFv fragments, VHH fragments or protein fragments or domains may be linked to immunoglobulin CH3 domains to form a homodimer. Protein fragments or domains may be linked to the N-termini of an Fc region to form homodimers. Protein fragments or domains may be linked to the C-termini of an Fc region to form homodimers or to both the N- and C-termini of an Fc region to form homodimers.
[0315] Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells (e.g. E. coli or phage). Methods for antibody fragmentation are known in the art (see, e.g., Andrew, Sarah M., and Julie A. Titus. "Fragmentation of immunoglobulin G." Current protocols in immunology 21.1 (1997): 2-8).
[0316] The "class" of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgGl, lgG2, lgG3, lgG4, IgAl, and lgA2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called a, 6, e, y, and p, respectively.The term "full length antibody" refers to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein. In a natural antibody molecule, there are two heavy chains and two light chains. Each heavy chain and each light chain has at its N-terminal end a variable domain. Each variable domain is composed of four framework regions (FRs) alternating with three complementarity determining regions (CDRs). The residues in the variable domains are conventionally numbered according to a system devised by Kabat et al. This system is set forth in Kabat et al., 1987, in Sequences of proteins of Immunological Interest, US Department of Health and Human Services, NIH, USA (hereafter "Kabat et al. (supra)"). This numbering system is used in the present specification except where otherwise indicated.
[0317] The antibody constant region domains of an antibody of the present disclosure, if present, for example in a full-length antibody or a multi-specific molecule, may be selected having regard to the proposed function of the multi-specific antibody molecule, and in particular the effector functions which may be required.
[0318] For example, the constant region domains may be human IgA, IgD, IgE, IgG or IgM domains. In particular, human IgG constant region domains may be used, especially of the IgGl and lgG4 isotypes.
[0319] In some embodiments, the antibody or antibody fragment may comprise a heavy chain constant region selected from IgGl, lgG2, lgG3 and lgG4. In preferred embodiments, the antibody molecule or antigen binding fragment comprises a heavy chain constant region of IgGl or lgG4. In further preferred embodiments, the antibody molecule or antigen binding fragment comprises a fully human IgGl heavy chain constant region having the sequence of SEQ ID NO. 375.
[0320] In embodiments, the antibody molecule comprises a light chain constant region of kappa. In embodiments, the antibody molecule comprises a light chain constant region of lambda. In preferred embodiments, the antibody molecule or antigen binding fragment comprises a human light chain constant region of kappa having the sequence of SEQ ID NO. 377.
[0321] In embodiments, the antibody molecule or antigen binding fragment comprises a fully human IgGl heavy chain constant region having the sequence of SEQ ID NO. 375 and a human light chain constant region of kappa having the sequence of SEQ ID NO. 377, paired with any of the VH and VL regions described herein.
[0322] In preferred embodiments, the antibody molecule or antigen binding fragment comprises a fully human IgGl heavy chain constant region having the sequence of SEQ ID NO. 376 and a human light chain constantregion of kappa having the sequence of SEQ. ID NO. 377 , paired with any of the VH and VL regions described herein. In such embodiments, the Fc region may preferably be afucosylated.
[0323] In embodiments, the antibody molecule is a rat antibody, a human antibody or a chimeric antibody.
[0324] A "rat antibody" is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a rat or rat cell or derived from a non-rat source that utilizes rat antibody repertoires or other rat antibody-encoding sequences.
[0325] A "human antibody" is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human or a human cell or derived from a non-human source that utilizes human antibody repertoires or other human antibody-encoding sequences. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.
[0326] A "chimeric antibody" is one which possesses an amino acid sequence which corresponds to that of an antibody produced by two or more species that utilizes two or more different species' antibody repertoires.
[0327] In embodiments, the antibody molecule or antigen binding fragment is humanized, optimised, and / or deimmunized.
[0328] A "humanized" antibody refers to a chimeric antibody comprising amino acid residues from non-human hypervariable regions (HVRs) and amino acid residues from human FRs. In certain embodiments, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization.
[0329] Standard antibody humanization techniques include engineering of a non-human framework to appear more human-like or adding non-human antibody features to a human framework. The non-human framework technique involves the comparison of amino acid sequences of a parent non-human antibody to the amino acid sequences of a similar human antibody. Subsequently, the amino acid sequence of the parent non-human antibody is altered such that its framework regions are more similar in sequence to the equivalent framework regions of the similar human antibody. In order to gain good binding capacities,development efforts need to be made for each immunobinder individually. The human framework technique involves all six murine CDRs being transferred onto a human antibody framework. The human framework technique involves the comparison of framework amino acid sequences of a parent nonhuman antibody to the framework amino acid sequences from a library of framework sequences from human antibodies. The comparisons are made using the sequence alignment techniques describe herein. A human framework sequence that is similar to that of the parent non-human antibody framework is selected. Similar sequences may be defined as the sequence with the highest % sequence identity. These CDR-grafted antibodies generally do not retain their original affinity for antigen binding and certain non-human framework residues must be incorporated into the variable domains to support structural conformation of the grafted CDRs and restore antigen binding and affinity. Many of the framework positions that are likely to affect affinity have been identified, thus structural modelling to select new residues in a stepwise fashion can generally lead to variants with restored antigen binding. Methods of antibody humanization are described in Queen, C. et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A 86, 10029-10033 (1989); Adair, J. R. et al. Humanization of the murine anti-human CD3 monoclonal antibody OKT3. Hum Antibodies Hybridomas 5, 41-47 (1994); and Carter, P. et al. Humanization of an anti-pl85HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 89, 4285-4289 (1992). Alternatively, phage antibody libraries targeted at these residues can also be used to enhance and speed up the affinity maturation process.
[0330] According to a further aspect of the invention, there is provided a humanized antibody or antigen binding fragment derived from the antibodies or antigen binding fragments described herein.
[0331] "Optimised" as employed herein is intended to refer to where one, two, three, four, five or more amino acids in a naturally occurring sequence have been replaced or deleted, for example to optimize the properties of the domain such as by eliminating undesirable properties but wherein the characterizing feature(s) of the domain is / are retained.
[0332] "De-immunized" refers to a technology for location and removal of T-cell epitopes through the combined use of immunological and molecular biology techniques. In the case of deimmunization of antibodies, mutations to remove T-cell epitopes can generally be introduced without significantly reducing the binding affinity (Kd) of the antibody. Typically, "deimmunized" antibodies are created with human constant regions and by expression of genes encoding these antibodies in mammalian cells.
[0333] In embodiments, the antibody molecule is monospecific. The term "monospecific" as used herein refers to the ability to bind only one target antigen.In embodiments, the antibody molecule is multispecific, for example bispecific. The term "multispecific" as used herein refers to antibodies that have binding specificities for at least two different sites.
[0334] In embodiments, the antibody or antigen-binding portion thereof comprises a first domain which binds CD161 and a second domain that specifically binds to a second molecule on the surface of a second cell.
[0335] In certain embodiments, the second cell is an effector cell. In certain embodiments, the effector cell comprises at least one of T cells, cytotoxic T-cells, natural killer (NK) cells, macrophages, neutrophils, eosinophils, dendritic cells, and monocytes.
[0336] By binding to both CD161 and a second molecule on the surface of an effector cell, the antibody or antigen-binding portion of the invention can be used to selectively localize the effector cell to cells which express CD161. This drives immune-mediated depletion of the CD161 target cells.
[0337] In certain embodiments, one of the binding specificities may be at least 70% for the amino acid sequence according to SEQ. ID NO. 256 of CD161 and the other binding specificity is for any other antigen.
[0338] Nucleic acid
[0339] According to an aspect of the present invention, there is provided nucleic acid encoding an antibody molecule or antigen binding fragment of any aspect of the invention.
[0340] A "nucleic acid" as described herein (or "isolated nucleic acid") refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in cells that ordinarily contain the nucleic acid molecule, but the nucleic acid molecule is present extra chromosomally or at a chromosomal location that is different from its natural chromosomal location.
[0341] Nucleic acids encoding the antibody or antigen-binding fragment of the invention can be used to produce the antibody or antigen-binding fragment of the invention. For example, nucleic acids encoding one or both of the heavy or light chains the antibody or antigen-binding fragment of the invention can be inserted into an expression vector.
[0342] VectorsAccording to an aspect of the present invention, there is provided an expression vector comprising a nucleic acid encoding an antibody molecule or antigen binding fragment according to any aspect of the invention.
[0343] The term "expression vector," as used herein, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked.
[0344] Host cell
[0345] According to an aspect of the present invention, there is provided a host cell comprising an expression vector according to the present invention.
[0346] The terms "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.
[0347] The host cell may be, but is not limited to, a mammalian cell, a plant cell, yeast or bacteria.
[0348] Compositions
[0349] According to an aspect of the present invention, there is provided a pharmaceutical composition comprising an antibody or antigen binding fragment according to the present invention, a nucleic acid according to the present invention, an expression vector according to the present invention, and / or a host cell according to the present invention.
[0350] The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier, diluent, excipient or adjuvant. Those skilled in the art will be familiar with pharmaceutically acceptable carriers, diluents, excipients or adjuvants which may be used to formulate antibodies and antigen binding fragments and examples of such materials are also provided herein.Appropriate formulations can be found in the formulary known to pharmaceutical formulators: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA . These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles, DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. See also Powell et al. "Compendium of excipients for parenteral formulations" PDA (1998) J Pharm Sci Technol 52:238-311.
[0351] The dose of the antibody or antigen binding fragment administered to a patient according to the present invention may vary depending upon the age and the size of the patient, symptoms, conditions, route of administration, and the like. The dose is typically calculated according to body weight or body surface area. Depending on the severity of the condition, the frequency and the duration of the treatment can be adjusted. Effective dosages and schedules for administering pharmaceutical compositions comprising antibodies or antigen binding fragments may be determined empirically; for example, patient progress can be monitored by periodic assessment, and the dose adjusted accordingly.
[0352] Various delivery systems are known and can be used to administer the antibodies or antigen binding fragments of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the mutant viruses, receptor mediated endocytosis (see, e.g., Wu et al., 1987, J. Biol. Chem. 262:4429-4432 ). Methods of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The composition may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents.
[0353] A pharmaceutical composition of the present invention can be delivered subcutaneously or intravenously with a standard needle and syringe. In addition, with respect to subcutaneous delivery, a pen delivery device readily has applications in delivering a pharmaceutical composition of the present invention. Such a pen delivery device can be reusable or disposable. A reusable pen delivery device generally utilizes a replaceable cartridge that contains a pharmaceutical composition. Once all of the pharmaceutical composition within the cartridge has been administered and the cartridge is empty, the empty cartridge can readily be discarded and replaced with a new cartridge that contains the pharmaceutical composition. The pen delivery device can then be reused. In a disposable pen delivery device, there is no replaceable cartridge. Rather, the disposable pen delivery device comes prefilled with the pharmaceutical composition held in a reservoir within the device. Once the reservoir is emptied of the pharmaceuticalcomposition, the entire device is discarded. Numerous reusable pen and autoinjector delivery devices have applications in the subcutaneous delivery of a pharmaceutical composition of the present invention. Examples include, but are not limited to AUTOPEN™ (Owen Mumford, Inc., Woodstock, UK), DISETRONIC™ pen (Disetronic Medical Systems, Bergdorf, Switzerland), HUMALOG MIX 75 / 25™ pen, HUMALOG™ pen, HUMALIN 70 / 30™ pen (Eli Lilly and Co., Indianapolis, IN), NOVOPEN™ I, II and III (Novo Nordisk, Copenhagen, Denmark), NOVOPEN JUNIOR™ (Novo Nordisk, Copenhagen, Denmark), BD™ pen (Becton Dickinson, Franklin Lakes, NJ), OPTIPEN™, OPTIPEN PRO™, OPTIPEN STARLET™, and OPTICLIK™ (sanofi-aventis, Frankfurt, Germany), to name only a few. Examples of disposable pen delivery devices having applications in subcutaneous delivery of a pharmaceutical composition of the present invention include, but are not limited to the SOLOSTAR™ pen (sanofi-aventis), the FLEXPEN™ (Novo Nordisk), and the KWIKPEN™ (Eli Lilly), the SURECLICK™ Autoinjector (Amgen, Thousand Oaks, CA), the PENLET™ (Haselmeier, Stuttgart, Germany), the EPIPEN (Dey, L.P.), and the HUMIRA™ Pen (Abbott Labs, Abbott Park IL), to name only a few.
[0354] In certain situations, the pharmaceutical composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, supra; Sefton, 1987, CRC Crit. Ref. Biomed. Eng.
[0355] 14:201 ). In another embodiment, polymeric materials can be used; see, Medical Applications of Controlled Release, Langer and Wise (eds.), 1974, CRC Pres., Boca Raton, Florida . In yet another embodiment, a controlled release system can be placed in proximity of the composition's target, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, 1984, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 ). Other controlled release systems are discussed in the review by Langer, 1990, Science 249:1527-1533.
[0356] The injectable preparations may include dosage forms for intravenous, subcutaneous, intracutaneous and intramuscular injections, drip infusions, etc. These injectable preparations may be prepared by known methods. For example, the injectable preparations may be prepared, e.g., by dissolving, suspending or emulsifying the antibody or its salt described above in a sterile aqueous medium or an oily medium conventionally used for injections. As the aqueous medium for injections, there are, for example, physiological saline, an isotonic solution containing glucose and other auxiliary agents, etc., which may be used in combination with an appropriate solubilizing agent such as an alcohol (e.g., ethanol), a polyalcohol (e.g., propylene glycol, polyethylene glycol), a non-ionic surfactant [e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)], etc. As the oily medium, there are employed, e.g., sesame oil, soybean oil, etc., which may be used in combination with a solubilizing agent such as benzyl benzoate, benzyl alcohol, etc. The injection thus prepared can be filled in an appropriate ampoule.Advantageously, the pharmaceutical compositions for oral or parenteral use described above are prepared into dosage forms in a unit dose suited to fit a dose of the active ingredients. Such dosage forms in a unit dose include, for example, tablets, pills, capsules, injections (ampoules), suppositories, etc.
[0357] "Pharmaceutically acceptable carriers", "pharmaceutically acceptable vehicles", "diluents" or "excipients" are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and / or non-ionic surfactants such as polyethylene glycol (PEG). Exemplary pharmaceutically acceptable carriers herein further include interstitial drug dispersion agents such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP), for example, human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX®, Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rHuPH20, are described in US Patent Publication Nos.
[0358] 2005 / 0260186 and 2006 / 0104968. In one aspect, a sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases.
[0359] An "adjuvant" is a drug or other substance, or a combination of substances, that is used to increase the efficacy or potency of certain drugs. It is an ingredient in a medicine that increases or modifies the activity of the other ingredients.
[0360] Antibody Production
[0361] According to an aspect of the present invention, there is provided a method of producing an antibody molecule or antigen binding fragment according to the present invention, the method comprising culturing a host cell according to the present invention under conditions suitable for gene expression.
[0362] Recombinant proteins, such as antibodies, are conventionally generated by transfecting the recombinant DNA into a host cell, following which the host cells are cultured and the transfected DNA transcribed and translated. Different host cells can be chosen for recombinant protein production, the choice of whichdepends on the type of protein that needs to be generated, its functional activity and requisite yield. Culturing a host cell under conditions suitable for gene expression allows for the expression of the recombinant DNA in the host cell and production of the required recombinant proteins.
[0363] Once translated, the antibody or antigen binding fragment can be isolated or purified by any suitable method known in the art which can be selected by the skilled person depending on the host cell.
[0364] In another aspect, the invention provides a method of producing an antibody molecule or antigen binding fragment according to any aspect of the invention, comprising a step of immunizing a host animal with an amino acid comprising the sequence according to SEQ ID NO. 256 of CD161, as an antigen, and a step of producing a polyclonal or monoclonal antibody.
[0365] "Immunizing" means to introduce immunogenic antigens, capable of eliciting an immune response, into an organism that results in said organism becoming protected to the disease associated with the antigens introduced.
[0366] A "host animal" is the animal into which a biologic or biologies are introduced.
[0367] "Antigen" means any substance that causes the body to produce an immune response against that substance.
[0368] The invention also provides an antibody molecule or antigen binding fragment thereof produced by administering to a host animal, an amino acid comprising the sequence the sequence according to SEQ ID NO. 256 of CD161 as an antigen, said antibody specifically binding to CD161 or a peptide fragment thereof.
[0369] Therapy
[0370] As explained herein, the antibodies and antigen binding fragments are capable of selectively depleting CD161+ cells. The identification and development of such antibodies by the inventors was based on their finding of the therapeutic value of CD161+ cell depletion while not substantially blocking CLEC2D / CD161 binding. Thus, according to a further aspect of the present invention, there is provided a method of treating or preventing an IM I D. This method may involve depleting CD161+ cells in a subject, the method comprising administering to the subject an antibody molecule or antigen binding fragment or a pharmaceutical composition of the present invention. Antibodies, antigen-binding fragments and compositions for use in such methods are also comprised within the present invention.As demonstrated in the examples, antibodies of the present invention have a profound and selective impact on CD161+ cell depletion. Further, as explained herein, CD161+ cells have been identified as producing a series of pro-inflammatory molecules including pro-inflammatory cytokines, pro-inflammatory chemokines and proinflammatory proteases.
[0371] The ability of the antibodies and antigen-binding fragments of the invention to deplete CD161+ cell populations which produce pro-inflammatory cytokines (e.g. IL-17 (A / F), IL-23, IL-22, I FNy, IL-26, TN Fa, IL-2, IL-21 and GM-CSF), pro-inflammatory chemokines (e.g. CSF2, CCL20 and CXCL13) and pro-inflammatory proteases (e.g. GZMB) means that they are of particular use in treating or preventing IMIDs mediated by any of these cytokines, chemokines and / or proteases.
[0372] Via the depletion of such populations of CD161+ cells, the antibodies, antigen binding fragments and other therapeutics discussed herein are effective for reducing the inflammatory response caused by those cytokines, chemokines and / or proteases. In addition, as the antibodies and antigen binding fragments of the invention do not compete with CLEC2D, they are able to simultaneously achieve clinically relevant reductions in one, some or all of these cytokines, chemokines and / or proteases without augmenting T cell activation. Therefore, the antibodies and antigen binding fragments detailed herein may be useful for treating or preventing IMIDs, in particular diseases or conditions mediated by one, some or all of these cytokines, chemokines or proteases.
[0373] In embodiments of the invention, administration of the antibody or antigen binding fragment of the present invention to the subject results in the reduced expression of immunostimulatory and / or pro-inflammatory cytokines, chemokines or other cell signalling molecules such as proteases. For example, the antibodies, antigen binding fragments and compositions of the invention may be useful for reducing or preventing elevation of the IL-17 (A / F), IL-23, IL-22, IFNy, IL-26, TNFa, IL-2, IL-21 and / or GM-CSF inflammatory response, which may be local or systemic. In addition, or alternatively, the antibodies, antigen binding fragments and compositions of the invention may be useful for reducing or preventing elevation of the CSF2, CCL20, CXCL13 or GZMB inflammatory response, which may be local or systemic.
[0374] In embodiments, the depletion of CD161+ cells reduces expression of IL-17 (A / F), IL-23, IL-22, IFNy, IL-26, TNFa, IL-2, IL-21 and / or GM-CSF in the subject. In certain embodiments, the antibodies, antigen binding fragments and compositions of the invention are for use in a method of reducing IL-17 (A / F), IL-23, IL-22, IFNy, IL-26, TNFa, IL-2, IL-21 and / or GM-CSF production in the treatment or prevention of an IM ID. In certain embodiments, the antibodies, antigen binding fragments and compositions of the invention are for use in treating or preventing an IM ID, wherein said treatment or prevention is achieved by reducing or preventing elevation of the IL-17 (A / F), IL-23, IL-22, IFNy, IL-26, TNFa, IL-2, IL-21 and / or GM-CSFinflammatory response. In certain embodiments, the antibodies, antigen binding fragments and compositions of the invention are for use in treating or preventing an IMID in a patient, wherein the patient has elevated levels of IL-17 (A / F), IL-23, IL-22, IFNy, IL-26, TN Fa, IL-2, IL-21 and / or GM-CSF.
[0375] In addition, or alternatively, the depletion of CD161+ cells reduces expression of CSF2, CCL20, CXCL13 and / or GZMB. In certain embodiments, the antibodies, antigen binding fragments and compositions of the invention are for use in a method of reducing CSF2, CCL20, CXCL13 and / or GZMB production in the treatment or prevention of an IMID. In certain embodiments, the antibodies, antigen binding fragments and compositions of the invention are for use in treating or preventing an IMID, wherein said treatment or prevention is achieved by reducing or preventing elevation of the CSF2, CCL20, CXCL13 and / or GZMB inflammatory response. In certain embodiments, the antibodies, antigen binding fragments and compositions of the invention are for use in treating or preventing an IMID in a patient, wherein the patient has elevated levels of CSF2, CCL20, CXCL13 and / or GZMB.
[0376] Examples of diseases and conditions that may be treated according to the methods and antibodies or antigen binding fragments described herein include hidradenitis suppurativa, psoriasis, psoriatic arthritis (PsA), juvenile idiopathic arthritis, axial spondyloarthritis (AxSpA), uveitis, multiple sclerosis, arthritis, such as rheumatoid arthritis, osteoarthritis, neuromyelitis optica (Devic's disease), ankylosing spondylitis, systemic lupus erythematosus, inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, celiac disease, asthma, such as allergic asthma or neutrophilic asthma, chronic obstructive pulmonary disease (COPD), scleritis, vasculitis, Behcet's disease, atherosclerosis, atopic dermatitis, emphysema, periodontitis, allergic rhinitis, and allograft rejection. In preferred embodiments, the methods and antibodies or antigen binding fragments of the invention are used for treating or preventing one or more of these conditions or diseases, preferably hidradenitis suppurativa, psoriasis (PsO), psoriatic Arthritis (PsA), axial spondyloarthritis (AxSpA), Crohn's disease, ulcerative colitis and uveitis. In further preferred embodiments, these conditions or diseases are mediated by IL-17 (A / F), IL-23, IL-22, IFNy, IL-26, TNFa, IL-2, IL-21 and / or GM-CSF.
[0377] In some embodiments, the pathogenesis of the disease or condition affects the skin.
[0378] As demonstrated in the examples, the methods and antibodies or antigen binding fragments described herein are capable of reducing CD161+ cell populations deep within tissue. Thus, the methods and antibodies or antigen binding fragments of the invention are not limited to the treatment of diseases to which the antibodies or antigen binding fragments are administered locally. Accordingly, in certain embodiments, the disease or condition is systemic.In certain embodiments, the patient may have been diagnosed with an I M ID, for example a chronic I M ID. Additionally, or alternatively, the antibody, antigen binding fragment or composition of the invention may be for use in preventing an IMID in a patient diagnosed with an IMID, identified as being at risk of developing an IMID or at risk of relapse of an IMID. In certain embodiments, the disease or condition may not be responsive to treatment with TNF-a inhibitors.
[0379] These uses of the invention may be applied to any of the specific disease or conditions listed herein. In certain embodiments, the methods and antibodies or antigen binding fragments described herein are for use in patients with chronic disease. In certain embodiments, the compositions are for use in preventing the development or an increase in the severity of chronic disease.
[0380] In embodiments, the IMID or auto-immune disease is mediated by IL-17 and / or IL-23. IL-17 is a pro-inflammatory cytokine required for a number of vital functions including the mediation of protective innate immunity.
[0381] IL-23 induces the differentiation of naive CD4+ T cells into pathogenic helper T cells (Thl7 / ThlL-17) that produce IL-17. IL-17 then induces the production of a number of pro-inflammatory cytokines that lead to disease, such as granulocyte colony-stimulating factor (G-CSF) and chemokines such as CXCL1 and CXCL28. Hence, the IL-17 / IL 23 axis plays a key role in inflammation in IMIDs.
[0382] Such diseases include, for example, Hidradenitis Suppurativa, Psoriasis (PsO), Psoriatic Arthritis (PsA), Axial spondyloarthritis (AxSpA), Inflammatory bowel disease (IBD), Uveitis. In some embodiments, the inflammatory or auto-immune disease is Hidradenitis Suppurativa (HS). Hence, in embodiments, the inflammatory or autoimmune disease is Hidradenitis Suppurativa, Psoriasis (PsO), Psoriatic Arthritis (PsA), Axial spondyloarthritis (AxSpA), Inflammatory bowel disease (IBD), or Uveitis.
[0383] Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition that primarily affects areas with apocrine sweat glands, such as the armpits, groin, and under the breasts. HS typically begins with follicular occlusion. This is the blockage of hair follicles. This blockage leads to the formation of comedones (blackheads) and subsequent inflammation. As the blocked follicles become inflamed, painful nodules, abscesses and sinus tracts result. Chronic inflammation can result in scarring and the development of tunnels under the skin. Changes in the skin microbiome occur, including the presence of certain bacteria, which contribute to the inflammation and infection commonly seen in HS.
[0384] https: / / pmc.ncbi.nlm nih.gov / articles / PMC5337858 / The immune system plays a significant role in the pathogenesis of HS. Inflammatory cytokines derived from T lymphocytes are involved in the ongoing inflammation and tissue damage. Based on therapeutic interventional studies, the TNF and IL-17 axis are key inflammatory nodes that contribute to HS pathobiology.
[0385] The IL-17 / IL-23 axis is also a key player in the pathogenesis of psoriasis, PsA, AxSpA, IBD and Uveitis. Hence, in affected individuals, I L-17 / 1 L-23 dysregulation is typically observed.
[0386] In PsA, IL-17 and IL-23 are involved in the chronic inflammation of the synovium (the lining of the joints). This inflammation leads to joint pain, swelling, and damage9. Similarly, in AxSpA, IL-17 signalling is crucial to the development of enthesitis (inflammation of the entheses, where tendons or ligaments attach to bone) and spondylitis (inflammation of the vertebrae), both of which are hallmark features of AxSpA10. Further, in IBD, the IL-23 axis is involved in the tissue damage observed in IBD. IL-23 amplifies the inflammatory response by enhancing the activity of Thl7 cells, which leads to the destruction of the intestinal mucosa11. In addition, the I L-17 / 1 L-23 axis also plays a central role in the pathogenesis of uveitis, with downstream IL-17 signalling causing retinal pigment epithelium cell dysfunction.
[0387] In some embodiments the IMID to be prevented or treated, may be an autoimmune disease. In embodiments of the invention, the IMID may be a T-cell mediated disease. In certain embodiments, the IMID may be a B-cell mediated disease. In certain embodiments, the IMID may be mediated by both T and B cells. In some embodiments, the IMID may be mediated by IL-17 and / or IL-23. In embodiments of the invention, the IMID may be a dermatological condition.
[0388] The antibodies and antigen binding fragments of the invention may be administered using any suitable method to deliver them to a subject, such as a cell, a plurality of cells, or a multicellular organism, in particular an animal or a human, such as via injection, particularly intravenous, subcutaneous or intramuscular injection, among other methods identifiable by skilled persons.
[0389] The antibodies, antigen binding fragments or compositions of the invention (and any additional therapeutic agent) can be administered by any suitable means, such as intravenously (IV) or subcutaneously. Dosing can be by any suitable route, e.g. by injections, such as intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic. Various
[0390]
[0391] dosing schedules including but not limited to single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein.
[0392] The antibodies and antigen binding fragments of the invention would be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The antibodies and antigen binding fragments of the invention need not be, but are optionally formulated with, one or more additional antibody molecules or antigen binding fragments currently used to prevent or treat the disorder in question.
[0393] Suitably, the antibodies and antigen binding fragments of the invention, in particular the antibody molecule or antigen binding fragment, may be administered in a therapeutically effective amount. The term "therapeutically effective amount" means any amount which, as compared to a corresponding subject who has not received such amount, results in a clinical improvement of disease.
[0394] For the prevention or treatment of disease, the appropriate dosage of the antibodies and antigen binding fragments of the invention (used alone or in combination with one or more other additional therapeutic agents), will depend on the type of disease to be treated, the type of antibody molecule or antigen binding fragment, the severity and course of the disease, whether the antibodies or antigen binding fragments is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibodies or antigen binding fragments, and the discretion of the attending physician.
[0395] The antibody molecule or antigen binding fragment is suitably administered to the patient at one time or over a series of treatments. Where the agent is an antibody or antigen binding fragment, depending on the type and severity of the disease, about 1 pg / kg to 15 mg / kg (e.g. 0.1 mg / kg-10 mg / kg) of antibody or antibody fragment can be an initial candidate dosage for administration to the patient. This may be, for example, by one or more separate administrations, or by continuous infusion. One typical daily dosage might range from about 1 pg / kg to 100 mg / kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment would generally be sustained until a desired suppression of disease symptoms occurs. One exemplary dosage of the antibody or antibody fragment would be in the range from about 0.05 mg / kg to about 10 mg / kg. Thus, one or more doses of about 0.5 mg / kg, 2.0 mg / kg, 4.0 mg / kg or 10 mg / kg (or any combination thereof) may be administered to the patient.Such doses may be administered intermittently, e.g. every week or every three weeks (e.g. such that the patient receives from about two to about twenty, or e.g. about six doses of the antibody). An initial higher loading dose, followed by one or more lower doses may be administered. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays. The antibodies and antigen binding fragments of the invention may be administered at suitable time intervals, for example monthly.
[0396] The antibodies, antigen binding fragments or compositions of the invention can be used either alone or in combination with other therapeutic agents. For example, the antibodies and antigen binding fragments of the invention may be co-administered with at least one additional therapeutic agent.
[0397] In some embodiments, effective treatment may be demonstrated by slowing or halting the progression of the disease in the subject or reversing the disease. Suitably, the disease may be reversed partially, or completely. In some embodiments, complete reversal of the disease may be sufficient to result in curing of the disease.
[0398] In the context of the present disclosure, the term "subject" includes humans and mammals (e.g., mice, rats, pigs, cats, dogs, and horses). In suitable embodiments, subjects are mammals, particularly primates, especially humans. In suitable embodiments, subjects are livestock such as cattle, sheep, goats, cows, swine, and the like; poultry such as chickens, ducks, geese, turkeys, and the like; and domesticated animals particularly pets such as dogs and cats. In certain embodiments (e.g., particularly in research contexts) subject mammals will be, for example, rodents (e.g., mice, rats, hamsters), rabbits, primates, or swine such as inbred pigs and the like. Herein, the terms, "patients" and "subjects" may be used interchangeably. In addition, the term "subject" may be used to refer to a single cell, a cell population, a tissue or an organ.
[0399] The term "Immune mediated inflammatory disease" or "IMID" refers to diseases characterized by aberrant, uncontrolled inflammation. Despite their diverse clinical presentations, these diseases share a common molecular etiology - elevated expression of pro-inflammatory cytokines.
[0400] Presently available therapeutics for IMIDs and auto-immune disease typically target downstream pro-inflammatory cytokines implicated in the disease such as those listed above. However, targeting the cytokines directly does not address the underlying pathogenic cause. Thus, a cell population remains which aberrantly expresses the pathogenic cytokines. A complete immune resolution in the patient is therefore not achieved, meaning that there is no sustained durability of response.Various attempts have been made in the past to deplete pathogenic cell populations which aberrantly express pro-inflammatory cytokines implicated in IMIDs and auto-immune disease.
[0401] For example, Alemtuzumab is a monoclonal CD52 antibody used in the treatment of a number of IMIDs including multiple sclerosis. However, Alemtuzumab depletes all T cell and B cell subsets in the subject, meaning it is a high-risk treatment with a significant proportion of patients developing autoimmune thyroid dysfunction12.
[0402] Autologous Stem Cell Transplant (ASCT) is another treatment for autoimmunity which can be used to deplete pathogenic cell populations. However, ASCT typically depletes all immune cells in the patient, resulting in a high mortality and infection risk.
[0403] In addition, as the treatment is specific for CD161+ cells, only CD161+ cells are depleted. This treatment is therefore believed to be safer that other cell-depleting treatments such as Alemtuzumab and ASCT, discussed above.
[0404] As used herein the terms "treat", "treating" or "treatment" refer to a clinical improvement of a disease. A clinical improvement may be demonstrated by an improvement of the pathology and / or symptoms associated with the disease.
[0405] Definitions
[0406] Throughout the description and claims of this specification, the words "comprise" and "contain" and variations of them mean "including but not limited to", and they are not intended to (and do not) exclude other moieties, additives, components, integers or steps.
[0407] Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.
[0408] Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith.
[0409] https : / / pmc.ncbi.nlm.nih.gov / articles / PMC8971069 / #:~:text=Alemtuzumab%2C%20an%20effective%20disease%2 Dmodifying,can%20have%20similar%20clinical%20presentations.As used herein the terms "treat", "treating" or "treatment" refer to a clinical improvement of a disease. A clinical improvement may be demonstrated by an improvement of the pathology and / or symptoms associated with the disease.
[0410] Suitably, the treatment may comprise stratification of patients. "Treatment stratification" refers to the process of systematically arranging or categorizing patients based on their health status and other factors.
[0411] In some embodiments, the patient is non-responsive to standard biologies. "Failing" initial therapy or being "non-responsive" means the patient has not sufficiently responded to the initial therapy and therefore has not attained the desired suppression of disease symptoms. They have not demonstrated a significant clinical improvement, which may be demonstrated by an improvement of the pathology and / or symptoms associated with the disease. Initial therapies or standard biologies may include surgery, chemotherapy, radiation therapy, immunotherapy, targeted therapy, and / or hormone therapy.
[0412] Unless defined otherwise herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. For example, Singleton and Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d Ed., John Wiley and Sons, NY (1994); and Hale and Marham, The Harper Collins Dictionary of Biology, Harper Perennial, NY (1991) provide those of skill in the art with a general dictionary of many of the terms used in the invention. Although any methods and materials similar or equivalent to those described herein find use in the practice of the present invention, the preferred methods and materials are described herein. Accordingly, the terms defined immediately below are more fully described by reference to the Specification as a whole. Also, as used herein, the singular terms "a", "an," and "the" include the plural reference unless the context clearly indicates otherwise. Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively. It is to be understood that this invention is not limited to the particular methodology, protocols, and reagents described, as these may vary, depending upon the context they are used by those of skill in the art.
[0413] All patents, patent applications, publications of patent applications, and other material, such as articles, books, specifications, publications, documents, things, and / or the like, referenced herein are hereby incorporated herein by this reference in their entirety for all purposes, excepting any prosecution file history associated with same, any of same that is inconsistent with or in conflict with the present document, or any of same that may have a limiting affect as to the broadest scope of the claims now or later associated with the present document. By way of example, should there be any inconsistency orconflict between the description, definition, and / or the use of a term associated with any of the incorporated material and that associated with the present document, the description, definition, and / or the use of the term in the present document shall prevail.
[0414] The patent, scientific and technical literature referred to herein establish knowledge that was available to those skilled in the art at the time of filing. The entire disclosures of the issued patents, published and pending patent applications, and other publications that are cited herein are hereby incorporated by reference to the same extent as if each was specifically and individually indicated to be incorporated by reference. In the case of any inconsistencies, the present disclosure will prevail.
[0415] Aspects of the invention are demonstrated by the following non-limiting examples.
[0416] EXAMPLES
[0417] Example 1 - CD161+ expression is restricted to a pathogenic IL-17 producing immune populations
[0418] Punch biopsies were performed on HS and psoriasis lesions. Single cell RNA sequencing (scRNA-seq) analysis was performed on cells isolated therefrom.
[0419] The scRNA-seq revealed a number of immune cells within the skin lesions which were visualised in UMAP plots (Figures 1A and C). In particular, CD161+, CD8+, CD4+ and T reg cells were identified therein.
[0420] Expression of IL-17 A and / or F was examined within these cells (Figures IB and D). A dominant IL-17 expression signature was surprisingly observed within the CD161+ cells, indicating that CD161+ expression is restricted to a pathogenic IL-17 producing immune populations in HS and psoriasis.
[0421] Additional analysis was conducted to determine the expression of a number of other pro-inflammatory cytokines in CD161+ cells in PsO and HS lesional tissue (Figures 2A-C). In contrast to IL-17 negative cells, IL-17 expressing CD161+ populations surprisingly co-express a number of other pro-inflammatory mediators, a feature that was more prominent in cells derived from HS than PsO tissue. (Figures 2B and 2C). Thus, pathogenic IL 17-producing immune populations produce multiple pro-inflammatory mediators which drive HS and psoriasis.
[0422] Example 2 - CD161 is a selective marker on IL-17 producing T cellsTo determine whether CD161 is a selective marker on IL-17 producing T cells, healthy human PBMCs were stimulated with anti-CD3 / 28 (lug / ml) for 72h including brefeldin A (lOug / ml) for the last 6h of culture. Fluorescent antibodies to IL-17 and CD161 were used to stain cells for 2h on ice prior to flow cytometric analysis. Figures 3A and 3B demonstrate >95% of IL-17 producing cells also express CD161.
[0423] Example 3 - Identification of cell types for CD161 depletion
[0424] Figure 4 defines the gating strategy to identify CD161+ populations, including MAIT cells CD3+, CD8+, Va7.2+), Thl7 cells (CD3+CD4+CCR6+) and NK cells (CD3-CD56+) within human PBMC. CD161 expression was highest in Mucosal-associated invariant T (MAIT) cells with Natural Killer cells expressing the lowest (Figure 5).
[0425] Based on the low expression levels of CD161, NK cells depletion will be inefficient, thus minimising the risk of potential infection.
[0426] Example 4 - Generation of human chimeric antibody clones that bind to human / cyno CD161
[0427] Mouse and rabbit derived antibodies were assayed for binding to human or cynomolgus monkey ("cyno") CD161 protein extracellular domain (ECD) via ELISA.
[0428] Monoclonal antibodies were generated against human CD161 by immunising 10 BALB / c mice and 3 rabbits with 200ug human CD161 protein extracellular domain (ECD) (Uniprot® ID Q12918 (67-225). Animals received 3 immunisations and single cell CD161-specific B cells were sorted from both species. Following library preparation and next generation sequencing, 671 unique CD161 specific clones were identified in rabbits, with 110 clones selected for expression as human chimeric antibodies. For mice, 282 unique sequences were obtained, with 88 clones selected for expression as human chimeric antibodies and purified. All antibodies were expressed successfully and their binding activity to human (Figures 6, 8-12) and cynomolgus (Figure 7, 13-17) versions of the target was tested by ELISA. Human or cynomolgus CD161 ECD (2ug / ml) was coated on ELISA plates overnight and plates were subsequently incubated with CD161 purified antibodies. Peroxidase labelled secondary goat anti-human IgG was used to detect CD161 bound antibodies. A commercially sourced anti-CD161 antibody (HP-3G10, Fisher Scientific®) was included as a positive control. The EC5o values for mouse antibodies (Table 1) and rabbit antibodies (Table 2) binding to human and cynomolgus CD161 ECD protein are shown. 35% mouse (Table 1) and 80% rabbit (Table 2) chimeric antibodies exhibited potent binding to both human and cyno CD161 proteins.Table 1. Summary table of mouse derived antibodies to recombinant human or cyno CD161 protein
[0429] using ELISA (EC50).
[0430] Human CD161 Cyno CD161 M-008 0.0026 0.0092 M-015 0.0126 0.0143 M-017 0.0810 0.0733 M-020 2.6470 weak M-021 0.6111 weak M-023 0.7369 weak M-024 0.2421 weak M-025 0.1465 0.0549 M-029 0.0156 0.0763 M-030 0.1194 0.0507 M-031 1.2740 weak M-032 0.0528 0.0330 M-035 0.0563 weak M-036 2.7540 weak M-041 0.0129 0.0107 M-042 0.0203 0.0167 M-048 0.0562 0.7402 M-051 1.2990 weak M-053 0.5207 188.8 M-054 0.4081 weak M-055 0.4191 38.4300 M-058 0.0939 0.0245 M-061 weak weak M-068 weak weak M-074 0.0315 weak M-078 0.0921 weak M-083 0.0231 0.0277 M-092 0.0115 0.0328 M-098 402.3 weak M-104 0.0288 weak
[0431]
[0432] M-112 weak weak
[0433] M-114 0.0277 0.1357
[0434] M-124 2.6760 weak
[0435] M-131 0.0534 weak
[0436] M-136 0.1680 0.0260
[0437] M-138 0.0957 weak
[0438] M-167 weak weak
[0439] M-172 8.5190 24.6900
[0440] M-181 0.0542 0.0515
[0441] M-182 0.7504 7.1890
[0442] M-221 8.5880 weak
[0443] M-226 0.0768 0.2292
[0444] M-229 0.0934 weak
[0445] M-236 0.0149 0.0171
[0446] M-259 weak
[0447] M-261 0.1862 weak
[0448] M-282 6.3830 9.3540
[0449] HP-3G10 0.5529 0.3290
[0450] Isotype No Binding No Binding
[0451]
[0452] Table 2. Summary table of rabbit derived antibodies to recombinant human or cyno CD161 protein using ELISA (EC5o).
[0453] Human
[0454] CD161 Cyno CD161
[0455] R-006 0.034 0.007
[0456] R-007 0.011 0.009
[0457] R-008 0.201 0.045
[0458] R-009 2.565 0.058
[0459] R-010 weak 9.026
[0460] R-011 0.406 0.244
[0461] R-012 0.020 0.008
[0462] R-014 0.018 0.001
[0463] R-015 0.384 0.006
[0464]
[0465] R-017 0.015 0.003 R-020 0.067 0.078 R-025 0.005 0.042 R-027 0.265 0.405 R-031 0.056 0.267 R-034 0.031 0.010 R-036 0.033 0.020 R-037 0.073 0.080 R-039 0.195 0.359 R-041 7.854 19.980 R-045 0.034 0.027 R-047 0.011 0.013 R-049 0.020 20.490 R-050 0.018 0.012 R-052 0.130 0.060 R-053 0.005 0.015 R-054 0.384 0.020 R-056 0.356 0.183 R-061 0.015 0.019 R-065 0.008 0.010 R-073 0.752 0.497 R-074 1.398 0.953 R-075 0.030 0.020 R-078 0.666 0.828 R-081 0.006 0.016 R-084 0.027 0.042 R-087 0.010 0.020 R-088 2.957 4.319 R-090 0.047 0.038 R-098 0.011 0.022 R-102 0.003 0.016 R-104 0.678 0.847 R-lll 0.072 0.065 R-119 0.009 0.033
[0466]
[0467] R-123 0.035 0.050 R-124 0.071 0.073 R-125 0.022 0.013 R-128 0.325 0.088 R-133 0.127 0.239 R-140 0.031 0.027 R-145 0.168 0.155 R-147 0.003 27.79 R-149 0.007 0.001 R-151 0.002 0.000 R-168 18.160 5.338 R-171 0.001 0.073 R-174 0.011 0.019 R-177 0.048 0.043 R-185 0.039 0.102 R-187 0.015 0.011 R-190 0.058 0.032 R-191 0.023 0.006 R-197 0.028 0.029 R-206 0.025 0.027 R-211 0.007 0.005 R-212 0.017 0.056 R-214 0.017 0.083 R-216 0.021 0.036 R-217 0.039 0.065 R-231 0.010 0.093 R-232 0.002 0.027 R-239 0.017 0.029 R-240 0.024 0.038 R-255 0.093 0.080 R-256 1.322 weak R-288 0.024 0.040 R-293 0.027 0.029 R-330 0.097 0.174
[0468]
[0469] R-403 0.065 0.509
[0470] R-479 0.028 0.028
[0471] R-561 0.033 0.033
[0472] HP-3G10 0.553 0.419
[0473] Isotype No Binding No Binding
[0474]
[0475] These data demonstrate that the different antibodies which were generated had a range of binding potency to CD161. While an important factor in the identification of therapeutically effective antibodies and antigen binding fragments, binding potency was not definitive in terms of the selection of antibodies and antigen binding fragments of the invention.
[0476] Example 5 - CD161 transfected HEK293 / Flow cytometry cell surface binding
[0477] Mouse and rabbit derived human chimeric antibodies were incubated with HEK293 cells expressing human CD161 at the indicated concentrations. Cell surface bound antibodies were then detected with a fluorochrome conjugated secondary anti-human antibody.
[0478] To evaluate antibody binding to cell surface expressed CD161, human chimeric antibodies derived from mice and rabbits were incubated with overexpressing CD161-HEK293 cells for lh at 4°C. As a comparator from the prior art, the KW1.3.12 antibody described in W02021 / 080682 was prepared and included in the assay. To detect surface bound antibody samples were washed in PBS and subsequently incubated with lug / ml of FITC-conjugated anti-human IgG antibody for 30 mins at 4°C. The results are shown in Tables 3 and 4 below and are also shown graphically in Figure 18.
[0479] Table 3. Summary table of mouse derived antibodies
[0480] Mouse
[0481] clones (EC50) ng / ml
[0482] 8 161.9
[0483] 15 847.9
[0484] 29 127
[0485] 32 24244
[0486] 41 159.8
[0487] 58 1231
[0488] 83 175.6
[0489]
[0490] 136 336.3
[0491] 181 3381 282 126382 KW1.3.12 460
[0492]
[0493] Table 4 Summary table of rabbit derived antibodies
[0494] (EC50) Rabbit clones ng / ml 7 210.3 11 13381 14 118.3 15 236.5 17 466.1 31 905.7 34 279.3 36 834.3 45 708.8 47 232.4 50 140 52 2524 65 315.8 75 455 84 273.8 102 108.6 123 195.2 125 186.9 128 27303 140 359.1 145 3224 171 3135 174 159.1 190 146.5 191 685.2
[0495]
[0496] 197 182.6
[0497] 206 148
[0498] 211 157.8
[0499] 212 7569
[0500] 214 156.6
[0501] 231 1340
[0502] 239 106.2
[0503] 240 109.6
[0504] 255 6148
[0505] 293 683.6
[0506] 479 166.2
[0507] 561 725.6
[0508] KW1.3.12 460
[0509]
[0510] The majority of antibodies exhibited potent binding to CD161+HEK293 cells with half maximal binding shown for mouse (Table 3) and rabbit chimeric antibodies (Table 4)
[0511] These data demonstrate that the different antibodies which were generated had a range of binding potency to CD161. While an important factor in the identification of therapeutically effective antibodies and antigen binding fragments, binding potency was not definitive in terms of the selection of antibodies and antigen binding fragments of the invention.
[0512] Example 6 - Antibodies do not inhibit CLEC2D ligand binding
[0513] CLEC2D is the natural ligand for CD161. To evaluate the capacity of CD161-specific antibodies to compete with CLEC2D binding, a CLEC2D-Fc fusion protein was produced through transfection of CHO cells. The construct design included a bivalent fusion protein comprising of two CLEC2D copies joined by a flexible linker, with an Fc domain attached to the C-terminus of the second CLEC2D chain. The resultant fusion protein was biotinylated to enable fluorescence detection via streptavidin PE labelling. The bivalent CLEC2D-lg demonstrated strong labelling of CD161+ cells but no signal was observed to CD161- cells. To assess the inhibition of ligand binding by CD161-specific monoclonal antibodies (mAbs), a competition assay was established wherein CD161+ HEK293 cells were incubated with varying concentrations of CD161 or control mAbs with biotinylated CLEC2D-Fc (lOug / ml) and incubated for lh at 4C. Binding of CLEC2D-Fc was detected following incubation with a streptavidin-PE secondary at lug / ml for 30 mins at 4°C. These experiments revealed that CD161 antibodies exhibited differing potency and efficacy in inhibiting CLEC2D binding (Table 5) and Figures 19A and 19B (for mouse derived antibodies) and Figures 19C to 19G (forrabbit derived antibodies). Antibodies demonstrating inefficient inhibition of CLEC2D-Fc, defined by 4x IC5o of competitor molecule (KW1.3.12, disclosed in W02021 / 080682) were selected for testing in a ADCC and ADCP depletion assay.
[0514] Table 5. IC5o values
[0515] IC50
[0516] Clones (ng / ml)
[0517] M-8 269.9
[0518] M - 15 1976
[0519] M- 29 88.33
[0520] M - 32 8814
[0521] M - 41 195.6
[0522] M - 58 3426
[0523] M - 83 338.1
[0524] M - 136 475.5
[0525] M - 181 9192
[0526] M - 282 25506
[0527] R-7 311.5
[0528] R- 11 30357
[0529] R- 14 474.3
[0530] R- 15 539.8
[0531] R- 17 1488
[0532] R-31 3749
[0533] R-34 505.6
[0534] R-36 1176
[0535] R-45 1798
[0536] R-47 645.9
[0537] R-50 252.2
[0538] R-52 9861
[0539] R-65 957
[0540] R-75 2011
[0541] R - 84 820.3
[0542] R- 102 139.3
[0543]
[0544] R- 123 758.5
[0545] R- 125 427.1
[0546] R- 128 4345
[0547] R- 140 803.1
[0548] R- 145 12124
[0549] R- 171 6561
[0550] R- 174 164.6
[0551] R- 187 N / D
[0552] R- 190 350.4
[0553] R- 191 2680
[0554] R- 197 271.7
[0555] R- 206 163.9
[0556] R- 211 270.6
[0557] R- 212 N / D
[0558] R- 214 169.7
[0559] R- 231 4511
[0560] R- 239 60.9
[0561] R - 240 244.3
[0562] R- 255 6062
[0563] R- 293 2950
[0564] R-479 332.6
[0565] R- 561 1825
[0566] KW1.3.12 175.1
[0567]
[0568] Table 5.1 Imax values (%)
[0569] [Antibody] R-171 R-145 R140 R-128 R-123 KW1.3.12 ng / ml
[0570] 10000.0 67.7 54.6 97.5 9.6 85.3 99.0 3333.0 32.5 24.2 94.2 6.3 80.3 98.3 1111.0 7.5 7.9 61.3 -4.2 57.1 94.7 370.0 -0.4 0.4 28.3 -2.1 21.3 68.4 123.0 -11.7 -3.3 10.8 -1.7 0.4 34.6
[0571]
[0572] 41.0 -12.9 -4.2 1.3 -7.1 -2.9 12.5
[0573] 13.0 -7.5 -0.8 -2.9 -5.8 -5.4 -0.4
[0574]
[0575] Antibodies / antigen binding fragments of the invention also have a low Imax for CD161-CLEC2D binding, even at high antibody concentrations. For example, at a concentration of ~lpg / ml (llllng / ml) the antibody R145 has an Imax of 7.9 whereas the comparator antibody has an Imax of 94.7 at the same concentration. Therefore, not only do antibodies of the invention have an advantageous IC50 profile (they are not potent inhibitors of CLEC2D-CD161 binding and in fact do not substantially inhibit CLEC2D-CD161 binding), but they also have an advantageous Imax profile because they are not effective CLEC2D-CD161 binding inhibitors at any concentration. Imax can be a more useful metric since IC50 values do not account for the fact that antibodies of the invention are not capable of fully inhibiting CLED2D-CD161 interaction even at high or saturating concentrations.
[0576] This data demonstrates that advantageously, the antibodies / antigen binding fragments of the invention do not substantially block CLEC2D-CD161 binding. In contrast, the comparator antibody KW1.3.12 disclosed in W02021 / 080682 exhibited high competitiveness to CLEC2D for CD161 binding. This is demonstrated by both IC50 and Imax in Table 5 and 5.1. From the disclosures in W02023 / 028501 and WO2024 / 091919, it is anticipated that the antibodies described in those documents will exhibit similarly high levels of competitiveness.
[0577] Example 7 - Antibodies demonstrate potent and selective depletion of CD161+cells in vitro
[0578] % depletion of CD161+ cells was assayed for both mouse and rabbit derived antibodies. To determine the potency and efficacy of anti-CD161 IgGl antibodies to kill CD161+ target cells via Antibody dependent cellular cytotoxicity (ADCC) and Antibody-dependent cellular phagocytosis (ADCP), varying concentrations of non-ligand competing CD161-specific antibodies were incubated with human PBMCs for 48h in RPMI culture media. Isotype control was used as a negative control. Following incubation, samples were labelled with O.lug / ml of anti-human IL-18R-Vioblue, CD3-Viogreen, CD56 FITC, CD161-PE, CD8-PerCP vio700, Va7.2-APC, CD4 APC Vio770 for 18h on ice. All antibodies were purchased from Miltenyi® biotec. Peripheral MAIT cells (CD8+IL-18R+Va7.2+) within PBMCs were used as the target. Again, the KW1.3.12 comparator described in the prior art (W02021 / 080682) was also included in the study. The degree of MAIT cell depletion was assessed by quantifying the loss of CD8+IL-18R+Va7.2+cells within the total CD8+T cell population and the results are presented in Table 6 below and graphically in Figure 20.
[0579] Table 6. % Depletion and IC5o valuesAntibody % IC50 clone Depletion (ng / ml) M - 015 44.9 0.07 M - 032 35.3 0.2001 M - 058 32 0.1433 M - 083 38.9 0.0942 M - 136 28.7 0.3431 M - 181 38.2 0.0237 M - 282 21.7 2.526 Isotype 1.1 0.1328 KW1.3.12 34.1 0.4189
[0580] R-ll 45.14 0.0231 R- 17 38.9 0.0275 R-31 31.09 0.5246 R-36 31.4 0.0335 R-45 43.5 0.0714 R-52 42.3 0.0468 R-65 47 0.06 R-75 45.6 0.11 R- 145 52.65 0.1137 R- 171 23.84 0.1256 R- 123 49.9 0.0203 R - 128 36.6 0.04672 R- 190 40.3 0.0093 R- 191 38.74 0.0638 R-231 45.6 0.1253 R - 240 24.91 0.0172 R-255 42.16 0.0407 R-293 40.97 0.0654 R-561 40.32 0.1378 Isotype 2.685 0.8154 KW1.3.12 33.7 0.2322
[0581]
[0582] This data demonstrates that the antibodies and antigen-binding fragments of the invention achieved robust levels of depletion in the CD161+ cells of interest. By exhibiting this effect in vivo, the antibodies and antigen-binding fragments of the invention may be used to treat or prevent IMIDs through inhibiting the production of pro-inflammatory cytokines and chemokines otherwise produced by CD161+ cell populations.
[0583] Example 8 - Antibodies demonstrate potent depletion efficacy of CD161+ cells across target specific immune populations
[0584] CLEC2D-ligand non-competitive, CD161-specific antibodies were evaluated in ADCC / ADCP assays to determine their relative ability to deplete CD161+target cells within human PBMCs.
[0585] Briefly, IgGl WT antibodies were incubated with PBMCs for 48 h in RPMI supplemented with 10% FBS. Following incubation, cells were stained on ice for 18 h with 0.1 pg / ml each of anti-human IL-18R-Vioblue, CD3-Viogreen, CD56-FITC, CD161-PE, CD8-PerCP-Vio700, Va7.2-APC, and CD4-APC-Vio770. Samples were then washed and fixed in 0.4% PFA. Depletion of defined immune subsets - including MAIT cells (CD8+I L- 18R+Va7.2+), CD4+T cells (CD3+CD4+), CD8+T cells (CD3+CD8+Va7.2"), and NK cells (CD56+CD3") - was quantified by flow cytometry.
[0586] The results are shown in Figure 21, where it is demonstrated the CLEC2D non-competitive antibodies demonstrate broad depletion potential in various target specific cell types that express CD161. Furthermore, it is demonstrated that clone R145 (rabbit derived) exhibits the highest efficiency of depletion across all target specific immune populations.
[0587] Example 9 - Antibodies demonstrate superior depletion over competitor antibodies
[0588] Antibodies of the invention were benchmarked against comparator CD161 antibodies from the prior art using ADCC / ADCP assays to establish superior depletion.
[0589] Briefly, human PBMCs were incubated for 48 h in RPMI with varying concentrations of CD161-specific IgGl WT antibodies. After incubation, cells were stained on ice for 18 h with 0.1 pg / ml of anti-human IL-18R-Vioblue, CD3-Viogreen, CD56-FITC, CD161-PE, CD8-PerCP-Vio700, Va7.2-APC, and CD4-APC-Vio770 (all antibodies from Miltenyi® Biotec). Peripheral MAIT cells (CD8+1 L- 18R+Va7.2+) within PBMCs served as the target population. MAIT-cell depletion was quantified by measuring the reduction of CD8+1 L- 18R+Va7.2+cells within the total CD8+Va7.2+T-cell compartment, and results are reported as percent depletion.The antibodies tested in this assay were as follows:
[0590] • Antibodies of the present invention (clones R-145 and R-011)
[0591] • The comparator antibodies identified as KW1.3.12, KW1.2.1 and KW7.3.7 in W02021 / 080682 (Dana Faber)
[0592] • The comparator antibodies identified as Hu47A5H2-ll, Hu50A8F2-04 and 22F10G3 in WO2024 / 091919 (Brigham & Women's)
[0593] • The comparator antibodies identified as Ab9 in US12215159B2 (Immunitas)
[0594] The results are shown in Figure 22. Not only are the antibodies of the invention ligand non-competitive, but they also demonstrate superior (and selective) depletion over comparator antibodies in ADCC / ADCP assays. By exhibiting this effect in vivo, the antibodies and antigen-binding fragments of the invention are better suited than comparator antibodies for treating or prevent IMIDs through inhibiting the production of pro-inflammatory cytokines and chemokines otherwise produced by CD161+ cell populations.
[0595] Example 10 - Antibodies demonstrate Fc-independent killing
[0596] Following the positive results demonstrating the advantages profile of antibodies of the invention when it comes to Fc-dependent killing mechanisms (such as ADCC, ADCP and CDC), antibodies of the invention were assayed for any effects they might have on CD161-expressing cells in the absence of Fc-mediated effector functions.
[0597] Briefly, varying concentrations of anti-human CD161 antibodies were incubated with Freestyle™ 293-F Cells engineered to express the human CD161 protein (CD161+ Freestyle™ 293-F Cells). Antibody-cell mixtures were incubated for 3h in complete RPMI cell culture media (RPMI supplemented with 10% FBS). An isotype control antibody was used as a negative control. Following incubation, samples were stained with LIVE / DEAD™ Fixable Near-IR Dead Cell Stain Kit (Invitrogen) for 20 minutes on ice. Cells were resuspended in complete RPMI culture medium with 0.4% paraformaldehyde (PFA). The extent of CD161+ Freestyle™ 293-F Cell depletion was determined by measuring the proportion of viable cells within the total cell population and normalising these values to the isotype control. The resulting data are summarized in Figure 23.
[0598] Antibodies used:
[0599] • R-145 - an antibody clone of the present invention
[0600] • REA-001_026 - a humanized variant of R145 clone
[0601] • Ab9 Immunitas - a comparator antibody from the prior art.This data demonstrates that the antibodies of the invention (both parental and humanized) induced depletion of CD161+ cells in an Fc-independent manner and achieved greater killing on HEK-293 cells expressing CD161 compared to comparator antibody Ab9. Without being bound by theory, it is theorised the antibodies of the invention may be killing directly, for example via cross linking the receptor. This highlights the functionality of the present antibodies alone, without reliance on the host immune system.
[0602] Example 11 - Humanization of murine and rabbit clones
[0603] Human chimeric mouse and rabbit derived antibodies (see Example 4) were humanized. Any method of antibody humanization known in the art may suitably be applied, including methods described in Queen et al, Adair et al and Carter et al as cited in this application. Briefly, amino acids in the chimeric mouse and rabbit parent antibodies that are responsible for antigen binding are identified (typically amino acids from the CDRs and / or hypervariable loops) and grafted onto a human antibody framework. The human antibody framework can be selected via a "best-fit" approach by choosing the human sequence with the highest homology to the non-human antibody to increase the chances of successful retention of affinity. Either mature or germline gene sequences may be used as sources for human sequences, although germline sources are preferred since germline sequences typically have a higher plasticity and are also less likely to contain immunogenic amino acids as they have not undergone hypersomatic mutation. Once the chimeric mouse or rabbit CDRs have been grafted onto a human framework, there may be a decrease in antigen binding affinity (Kd) due to incompatibilities between the human framework and non-human CDRs. Back-mutations are therefore introduced to retain a certain amount of non-human amino acids within the framework regions. Typically, the amino acids of most interest for back mutation (reversion to the canonical mouse or rabbit amino acid) are those in the Vernier Zone or canonical structural residues (CSRs).
[0604] The following humanized antibodies were derived from clone R145 (See Figure 27):
[0605] REA001_A_019 (see Sequence Tables 8 and 9)
[0606] REA001_A_020 (see Sequence Tables 8 and 9)
[0607] REA001_A_021 (see Sequence Tables 8 and 9)
[0608] REA001_A_022 (see Sequence Tables 8 and 9)
[0609] REA001_A_023 (see Sequence Tables 8 and 9)
[0610] REA001_A_024 (see Sequence Tables 8 and 9)
[0611] REA001_A_025 (see Sequence Tables 8 and 9)
[0612] REA001_A_026 (see Sequence Tables 8 and 9)
[0613]
[0614] Example 12 - Humanized antibodies exhibit on-cell CD161 affinityThe humanized antibodies were assayed and found to exhibit similar binding profiles to comparator antibodies on CD161 expressing cells. To evaluate antibody binding to cell surface expressed CD161, R145 humanized variants were incubated with CD161-expressing HEK293 cells for lh at 4C. Samples were then washed in PBS and cell surface bound CD161 antibodies were then stained with a goat-anti-human AF488 secondary (lug / ml) for 30 mins. As a comparator from the prior art, the Immunitas A9 antibody as described in US12215159B2 was included. The results are shown as geometric mean fluorescence in Figure 24.
[0615] This demonstrates that the humanized antibodies are functional and retain their ability to bind cell surface expressed CD161.
[0616] Certain humanized antibodies were further interrogated to evaluate antibody binding affinity (Kd) to cell expressed CD161. Humanized antibody REA001_A_026 (REA001) was compared to comparator antibodies for binding to CD161-expressing HEK293 cells. Varying concentrations of antibodies were incubated with HEK293F-CD161 cells for lh at 4C. Samples were subsequently washed in PBS before being stained with goat-anti-human AF488 secondary (lug / ml) for 30 mins. Antibody binding is shown as geometric mean fluorescence. Humanized antibody REA001_A_026 was then compared to comparator antibodies for binding to CD161-expressing HEK293 cells relative to their depletion potential in ADCC / ADCP assays. The results are shown in Figure 25 and Table 6.1.
[0617] Table 6.1 (depletion efficacy vs on-cell affinity as shown in Figure 25)
[0618] Antibody Depletion efficacy On-cell affinity (nm)
[0619] REA001 51.20 5.15
[0620] KW1.3.12 29.10 4.59
[0621] KW1.2.1 23.50 2.78
[0622] KW7.3.7 20.30 3.47
[0623] HU47A5H2-11 27.40 0.85
[0624] Hu50A8F2-04 3.00 99.56
[0625] 22F10G3 20.65 3.13
[0626] Ab9 17.50 1.64
[0627]
[0628] The humanized antibodies of the invention exhibit on-cell CD161 affinity on par with comparator antibodies, while surprisingly achieving substantially greater depletion potency.The humanized antibodies of the invention are also assayed to confirm they also do not substantially block CLEC2D-CD161 binding. It would be expected the humanized antibodies would share this property with the parental rabbit antibodies from which they derive. To evaluate the capacity of CD161-specific antibodies to compete with CLEC2D binding, a CLEC2D-Fc fusion protein is produced through transfection of CHO cells. The construct design includes a bivalent fusion protein comprising of two CLEC2D copies joined by a flexible linker, with an Fc domain attached to the C-terminus of the second CLEC2D chain. The resultant fusion protein is biotinylated to enable fluorescence detection via streptavidin PE labelling. To assess the inhibition of ligand binding by the humanized antibodies, a competition assay is established wherein CD161+ HEK293 cells were incubated with varying concentrations of CD161 or control mAbs with biotinylated CLEC2D-Fc (lOug / ml) and incubate for lh at 4C. Binding of CLEC2D-Fc is detected following incubation with a streptavidin-PE secondary at lug / ml for 30 mins at 4°C.
[0629] Example 13 - Antibodies bind a distinct epitope relative to comparator antibodies
[0630] The antibodies of the invention were assessed for binding competition with various internal and comparator antibodies to determine which antibodies compete for the same binding epitope.
[0631] A total of 8,000 HEK293F-huCD161 (REA-001_C_001) cells, generated by overexpression of human CD161 (Biointron), were pre-incubated at 4 °C for 30 min with varying concentrations (0.1,l,10mg / ml) of anti-CD161 antibodies as described herein (antibody R011) or with comparator antibodies from Immunitas (Ab09 / IMT-009) and Dana-Farber (KW1.3.12). Following three washes, the cells were incubated with l pg / mL of parental antibody R145, pre-labelled with Alexa Fluor 488 (A488) using commercially available Zenon human IgG labelling kit (Invitrogen, cat#:Z25402). Flow-cytometric assessment of R145-A488 binding was then carried out.
[0632] The results are shown in Figure 26. Even at the highest concentrations of CD161 pre-labelling with comparator anti-CD161 antibodies or other antibody clones (such as Rll), the parental R145 antibody is still able to bind CD161, suggesting that R145 may recognize a distinct epitope. Although R145 binding is still detectable following pre-occupation of CD161 by other anti-CD161 antibodies, high-concentration preincubation with the Immunitas or Dana-Farber antibodies results in partial competition. This could indicate steric hindrance or differences in affinity that reduce R145 binding in this circumstance.
[0633] This finding was further confirmed using in silico epitope mapping. This was undertaken using the software platform: Molecular Operating Environment (MOE), 2024.0601 Chemical Computing Group ULC, 910-1010 Sherbrooke St. W., Montreal, QC H3A 2R7, 2026. It was confirmed that comparator anti-CD161antibodies bind a similar epitope to the natural ligand CLEC2, directly inhibiting binding of CLEC2D to CD161 and releasing the inhibition on T cell activation. However, antibodies of the invention are found (via in silico epitope mapping) to bind a different epitope, meaning there is only minimal competition with natural ligand CLEC2D. Due to this new epitope, the antibodies and antigen binding fragments of the present invention do not block the interaction between CLEC2D and CD161, meaning CLEC2D is still able to bind to CD161 and suppress T cell activation.
[0634] SEQUENCES
[0635] Table 7. CDR combinations
[0636] All CDRs are numbered according to the Kabat system unless otherwise indicated.
[0637] Clone No. VH CDRs (HCRD1, HCDR2, HCDR3) VL CDRs (LCDR1, LCDR2, LCDR3) M-15 SYTMS (SEQ ID NO. 1) RASEGVEYYGTSFMQ (SEQ ID NO. 4)
[0638] YINNAGGSTYYPDTVKG (SEQ ID NO.2) AASNVES (SEQ ID NO. 5) HSFYGDHGAMDY (SEQ ID NO. 3) QQTRKVPST (SEQ ID NO. 6)
[0639] M-32 DYIIH (SEQ ID NO. 7) HASQNINVWLS (SEQ ID NO. 10)
[0640] GINPNNGGTTYNQKFKA (SEQ ID NO. KASNLHT (SEQ ID NO. 11)
[0641] 8) QQGQSYPLT (SEQ ID NO. 12) PYYYSYAMDS (SEQ ID NO. 9)
[0642] M-58 SFWIQ(SEQ ID NO. 13) RASSSVSSSYLH (SEQ ID NO. 16)
[0643] KIFPGTGTTDYNEKFKG (SEQ ID NO. STSNLAS (SEQ ID NO. 17)
[0644] 14) QQYSGYPLT (SEQ ID NO. 18)
[0645] Il l i IGWFAY (SEQ ID NO. 15)
[0646] M-181 SFGMH (SEQ ID NO. 19) RASESVDSYGNSFMH (SEQ ID NO.
[0647] YISGGSRTIYYADTVKG (SEQ ID NO. 20) 22)
[0648] DGIYAMDY (SEQ ID NO. 21) RASNLES (SEQ ID NO. 23)
[0649] QQNFEEPWT (SEQ ID NO. 24)
[0650] R-17 RYAMG (SEQ ID NO. 25) QSSQSVYDNNDLS (SEQ ID NO. 28)
[0651] VISSAGSTYYASWAK (SEQ ID NO. 26) RASNLAS (SEQ ID NO. 29) RLYVDGYAGLDFNI (SEQ ID NO. 27) DDAATYYCLGGYDDDAANA (SEQ ID NO. 30)
[0652]
[0653] R-36 GYYMS (SEQ ID NO. 31) QASQNIYSNLA (SEQ ID NO. 34)
[0654] IISYGGTTYDANWA (SEQ ID NO. 32) RASTLAS (SEQ ID NO. 35) GPDIDYFDL (SEQ ID NO. 33) QGYDYSSGYVYVNA (SEQ ID NO. 36)
[0655] R-45 SNAMS (SEQ ID NO. 37) QASESVYSNLA (SEQ ID NO. 40)
[0656] IINDSGNADYASWS (SEQ ID NO. 38) AASNLAS (SEQ ID NO. 41) DLYAGYADYYYGMDL (SEQ ID NO. 39) QSPYWSSTADSIA (SEQ ID NO. 42)
[0657] R-52 SYYMS (SEQ ID NO. 43) QASQSVYGNNQLS (SEQ ID NO. 46)
[0658] YIASGGATYYASWA (SEQ ID NO. 44) GASTLAS (SEQ ID NO. 47) VQTYETIAIGVFNL (SEQ ID NO. 45) DDAATYYCQGGYSSITDTIA (SEQ ID NO. 48)
[0659] R-65 NYYMS (SEQ ID NO. 49) QSSQSVFSNNWLA (SEQ ID NO. 52)
[0660] IIAPIGSTYYASWV (SEQ ID NO. 50) LASTLAS (SEQ ID NO. 53) GDYTGYDI (SEQ ID NO. 51) DDAATYYCAGDYNGNIFT (SEQ ID NO. 54)
[0661] R-128 NYAMI (SEQ ID NO. 55) QASQSIDSNLA (SEQ ID NO. 58)
[0662] VIASSGNTYYASWA (SEQ ID NO. 56) RASTLES (SEQ ID NO. 59) DGFYDNVGYVYAYFNI (SEQ ID NO.57) QGYYYSSSASYA (SEQ ID NO. 60)
[0663] R-145 (Kabat) NYNMG (SEQ ID NO. 61) QASQSIGSDLA (SEQ ID NO. 64)
[0664] VIISSGSTYYASWV (SEQ ID NO. 62) GASNLES (SEQ ID NO. 65) LYVSSSGYNI (SEQ ID NO. 63) QSALYGNNYIGYG (SEQ ID NO. 66)
[0665] R-145 (IMGT) GFSLSNYN (SEQ ID NO. 348) QSIGSD (SEQID NO. 351)
[0666] IISSG (SEQ ID NO. 349) GAS (SEQ ID NO. 352) ARLYVSSSGYNI (SEQ ID NO. 350) QSALYGNNYIGYG (SEQ ID NO. 353) R-190 SSYMN (SEQ ID NO. 67) QSSQRIYSANWLG (SEQ ID NO. 70)
[0667] IIDDRNNTWYANWA (SEQ ID NO. 68) RASTLAS (SEQ ID NO. 71) DIDHDGDHDGFYP (SEQ ID NO. 69) DDAATYYCAGAYYDYRA (SEQ ID NO.
[0668] 72)
[0669] R-191 SYAMG (SEQID NO. 73) QASQSIGSNLA (SEQ ID NO. 76)
[0670]
[0671] IIDPNTNTWYASWV (SEQ ID NO. 74) RASNLAS (SEQ ID NO. 77)
[0672] DRYPDYSMYTFDL (SEQ ID NO. 75) QQGYSGSDIHNT (SEQ ID NO. 78)
[0673] R-231 SYYMN (SEQ ID NO. 79) QASQSISNYLA (SEQ ID NO. 82)
[0674] IISFGGSAYYTTWAE (SEQ ID NO. 80) GASTLAS (SEQ ID NO. 83) IYGYYIGWGPSNI (SEQ ID NO. 81) QSYYGGSSTYGSDINV (SEQ ID NO.
[0675] 84)
[0676] R-255 TYYMS (SEQ ID NO. 85) QASQSVYGNNQLS (SEQ ID NO. 88)
[0677] YIASGGNTYYATWA (SEQ ID NO. 86) DASTLAS (SEQ ID NO. 89) VQTYTAVGYAIAKGYFNL (SEQ ID NO. DDAATYFCQGGYSSITDTIA (SEQ ID 87) NO. 90)
[0678] R-ll SYYMS (SEQ ID NO. 260) QASQSVYGNNQLS (SEQ ID NO.
[0679] YITSGGNTYYASWA (SEQ ID NO. 261) 263)
[0680] VQTYDTIAIGVFNL (SEQ ID NO. 262) GASTLAS (SEQ ID NO. 264)
[0681] DDAATYYCQGGYSSITDTIA (SEQ ID NO. 265)
[0682] R-123 NSYMN (SEQ ID NO. 266) QSSQRIYSANWLG (SEQ ID NO. 269)
[0683] IIDDRNNTWYANWA (SEQ ID NO. RASTLAS (SEQ ID NO. 270) 267) DDAATYYCAGAYYDYRA (SEQ ID DIDHDGDHDGFYP (SEQ ID NO. 268) NO. 271)
[0684] M-282 TYWMH (SEQ ID NO. 276) SARSSVNYMH (SEQ ID NO. 279)
[0685] TIYPAIGHTNYDDKFKS (SEQ ID NO. DTSKLAS (SEQ ID NO. 280) 277) QQWSSDPLT (SEQ ID NO. 281) SGFD (SEQ ID NO. 278)
[0686] R-31 SYYMS (SEQ ID NO. 282) QASQSIGSNLA (SEQ ID NO. 285)
[0687] IIYAGSGTTWYASWV (SEQ ID NO. RASTLAS (SEQ ID NO. 286) 283) QGYHYDISSGYDFA (SEQ ID NO. QYADSAGYGYVDTFDP (SEQ ID NO. 287)
[0688] 284)
[0689]
[0690] R-75 SYAMG (SEQID NO. 288) QSSQSVYANNWLS (SEQ ID NO.
[0691] IIFEDGNTYYATWAK (SEQ ID NO. 289) 291)
[0692] VNFNI (SEQ ID NO. 290) LASTLAS (SEQ ID NO. 292)
[0693] DDAATYYCQGGYSSNIYP (SEQ ID NO. 293)
[0694] R-171 SGYMS (SEQ ID NO. 294) QASQSAGNTLA (SEQ ID NO. 297)
[0695] IIDTGSGSTWYASWV (SEQ ID NO. RASTLAS (SEQ ID NO. 298) 295) QSYDYSHGFSYDFA (SEQ ID NO. TYYDSNGYAYVDVFDS (SEQ ID NO. 299)
[0696] 296)
[0697] R-185 SNVIS (SEQ ID NO. 300) QASQSVYKNNYLA (SEQ ID NO. 303)
[0698] DIYSDGATYCASWA (SEQ ID NO. 301) YASTLAS (SEQ ID NO. 304) IGYKTGTI (SEQID NO. 302) DDAATYYCQGEFSCSSADCIA (SEQ ID NO. 305)
[0699] R-212 SYGMI (SEQ ID NO. 306) QSSQSVYNNNALS (SEQ ID NO. 309)
[0700] WMDLDGRTWYASWA (SEQ ID NO. KASTLAS (SEQ ID NO. 310) 307) DDAATYYCTGDYSSASDIT (SEQ ID PGYNTGIWL (SEQ ID NO. 308) NO. 311)
[0701] R-240 TYAMN (SEQ ID NO. 312) QASQNIESYLA (SEQ ID NO. 315)
[0702] IIDAGGAAYYASWA (SEQ ID NO. 313) AASNLAS (SEQ ID NO. 316) VYDGYPYAYAYHGMDL (SEQ ID NO. QGYDSDYING (SEQ ID NO. 317) 314)
[0703] R-293 NCWMA (SEQ ID NO. 318) QSSQSVSVNRLS (SEQ ID NO. 321)
[0704] WISPDGKAYYATWT (SEQ ID NO. 319) DASKLIS (SEQ ID NO. 322) YFFFDNTAIFDS (SEQ ID NO. 320) AAEYTGAIYT (SEQ ID NO. 323) R-561 SYIMS (SEQ ID NO. 324) QASQSVYGNNWLA (SEQ ID NO.
[0705] VISGSVNTNYATWA (SEQ ID NO. 325) 327)
[0706] ADLGL (SEQ ID NO. 326) SASTLDS (SEQ ID NO. 328)
[0707] DDAATYYCAGGYSGDLYV (SEQ ID NO. 329)
[0708] Humanized vl-v8 NYNMG (SEQ ID NO. 61) RASQSIGSDLA (SEQ ID NO. 355) (Kabat) REA- VIISSGSTYYASSVKG (SEQ ID NO. GASNLES (SEQ ID NO. 65) 001_A_019; 354) QSALYGNNYIGYG (SEQ ID NO. 66) REA-001_A_020; LYVSSSGYNI (SEQ ID NO. 63)
[0709] REA-001_A_021;
[0710]
[0711] REA-001_A_022;
[0712] REA-001_A_023;
[0713] REA-001_A_024;
[0714] REA-001_A_025;
[0715] REA-001_A_026.
[0716] Humanized vl-v8 GFSLSNYN (SEQ ID NO. 348) QSIGSD (SEQ ID NO. 351)
[0717] (IMGT) REA- IISSGST (SEQ ID NO. 356) GAS (SEQ ID NO. 352) 001_A_019; ARLYVSSSGYNI (SEQ ID NO. 350) QSALYGNNYIGYG (SEQ ID NO. 353) REA-001_A_020;
[0718] REA-001_A_021;
[0719] REA-001_A_022;
[0720] REA-001_A_023;
[0721] REA-001_A_024;
[0722] REA-001_A_025;
[0723] REA-001_A_026.
[0724]
[0725] Each of the CDR combinations in Table 7 may be paired with a heavy chain constant region comprising an Fc region, and a light chain constant region. In such embodiments the heavy chain constant region comprises the sequence of SEQ ID NO. 375 and the light chain region comprises the sequence of SEQ ID NO. 377.
[0726] Each of the CDR combinations in Table 7 may be paired with a heavy chain constant region comprising an Fc region comprising the mutation K439E, and a light chain constant region. In such embodiments the heavy chain constant region comprises the sequence of SEQ ID NO. 376 and the light chain region comprises the sequence of SEQ ID NO. 377.
[0727] Each of the CDR combinations in Table 7 may be paired with a heavy chain constant region comprising an afucosylated Fc region, and a light chain constant region. In such embodiments the heavy chain constant region comprises the sequence of SEQ ID NO. 375 (afucosylated) and the light chain region comprises the sequence of SEQ ID NO. 377.
[0728] Each of the CDR combinations in Table 7 may be paired with a heavy chain constant region comprising an afucosylated Fc region comprising the mutation K439E, and a light chain constant region. In suchembodiments the heavy chain constant region comprises the sequence of SEQ ID NO. 376 (afucosylated) and the light chain region comprises the sequence of SEQ ID NO. 377.
[0729] Table 8. VH and VL combinations
[0730] Clone No. VH VL
[0731] M-15 EVKLVESGGGLVQPGGSLKLSCAAS DIVLTQSPASLAVSLGQRATISCRAS GFTFSSYTMSWVRQTPEKRLEWVAY EGVEYYGTSFMQWYQQKPGQPPK INNAGGSTYYPDTVKGRFTISRDNAK LLIYAASNVESGVPARFSGSGSGTDF NTLYLQMSSLKSEDTAMYYCARHSF SLNIHPVEEDDIAMYFCQQTRKVPS YG D HG AM DYWGQGTSVTVSS TFGGGTKLEIK (SEQ ID NO. 92) (SEQ ID NO. 91)
[0732] M-32 EVQLLQSGPELVKPGASVKMSCKTS DIQMNQSPSSLSASLGDTITITCHAS GYTFTDYIIHWMRQSHGKSLEWIG QNINVWLSWYQQKPGNIPKLLIYKA GINPNNGGTTYNQKFKAKATLTVDK SNLHTGVPSRFSGSGSGTGFTLTISSL SSSTAYMELRSLTSEDSAVYFCGRPY QPEDIATYYCQQGQSYPLTFGGGTK YYSYAM DSWGQGTSVTVSS LEIT (SEQ ID NO. 94)
[0733] (SEQ ID NO. 93)
[0734] M-58 QVQLQQSGAEQVKPGASVKLSC ENVLTQSPAIMSASPGEKVTMTCR KTSGYSFTSFWIQWVKKRPGQGL ASSSVSSSYLHWYQQKSGASPKLW GWIGKIFPGTGTTDYNEKFKGKAT IYSTSNLASGVPPRFSGSGSGTSYSLT LTI DTSSSTAYM QLSS LTS E DS AVY ISSVEAEDAATYYCQQYSGYPLTFGA FCATI I l l i GWFAYWGQGTLVTVS GTKLELK (SEQ ID NO. 96)
[0735] A (SEQ ID NO. 95)
[0736] M-181 DVQLVESGGGLVQPGGSRKLSCA DIVLTQSPASLAVSLGQRATISCRASE ASGFTFSSFGMHWVRQAPEKGLE SVDSYGNSFMHWYQQKPGQPPKLL WVAYISGGSRTIYYADTVKGRFTISR MYRASNLESGIPARFSGSGSWTDFTL DNPKNTLFLQMTSLRSEDTAMYYC TINPVEADDVATYYCQQNFEEPWTF ARDGIYAM DYWGQGTSVTVSS GGGTKLEIK (SEQ ID NO. 98) (SEQ ID NO. 97)
[0737] R-17 QSLEESGGRLVTPGTPLTLTCTASGI AAVLTQTPSPVSAAVGGTVTISCQSS DLSRYAMGWVRQAPGKGLEYIGVIS QSVYDNNDLSWYQQKPGQPPKLLI SAGSTYYASWAKGRFTISKTSSTTVD YRASNLASGVPSRFSGTGSGTQFTLT LKMTSPTTEDTATYFCARRLYVDGYA ISGVQCDDAATYYCLGGYDDDAAN
[0738]
[0739] GLDFNIWGPGTLVTVSS (SEQ ID NO. 99) AFGGGTEVVVK (SEQ ID NO. 100)
[0740] R-36 QSVEESGGRLVTPGTPLTLTCTVSGF ALVMTQTPSSVSAAVGGTVTINCQA SLSGYYMSWVRQAPGKGLEWIGIIS SQN IYSN LAWYQQKPGQPPKLLIYRA YGGTTYDANWAKGRFTISKTSTTVDL STLASGVSSRFKGSRSGTEYTLTISDLE KITSPTTEDTATYFCARGPDIDYFDLW CADAATYYCQGYDYSSGYVYVNAF GQGTLVTVSS (SEQ ID NO. 101) GGGTEVVVK (SEQ ID NO. 102) R-45 AIEMTQTPFSVSAAVGGTVTINCQA QSLEESGGRLVTPGTPLTLTCTVSGF SESVYSNLAWYQQKPGQPPKLLIYA SLSSNAMSWVRQAPGKGLEWIGIIN ASNLASGVSSRFKGSGSGTEYTLTIS DSGNADYASWSKGRFTISKTSTTVDL GVQCADAATYYCQSPYWSSTADSI KITSPTTEDTATYFCARDLYAGYADYY AFGGGTEVVVE (SEQ ID NO. 104) YGMDLWGPGTLVTVSS (SEQ ID NO. 103)
[0741] R-52 QSLEESGGRLVTPGTPLTLTCTASGF AAVLTQTPSPVSAAVGGTVTISCQAS S LSS YYM SWVRQAPG KG LEYI G Yl A QSVYGNNQLSWYQQKPGQPPKLL SGGATYYASWAKGRFTISRTSTAVGL IYGASTLASGVPSRFKGSGSGTQFTL KLTSLTTEDTATYFCARVQTYETIAIGV TISDLECDDAATYYCQGGYSSITDTI FNLWGQGTLVTVSS (SEQ ID NO. 105) AFGGGTEVVVK (SEQ ID NO. 106) R-65 QSLEESGGRLVTPGTPLTLTCTASGF AQVLTQTASPVSAAVGGTVTI NCQS SLNNYYMSWVRQAPGKGLEYIGIIAP SQSVFSNNWLAWYQQKPGQPPKL IGSTYYASWVNGLFTISKTSTTVDLKM LISLASTLASGVPSRFSGSGSGTQFT TSPTTEDTATYFCARGDYTGYDIWGP LTISDLDCDDAATYYCAGDYNGNI GTLVTVSS (SEQ ID NO. 107) FTFGGGTEVVVK (SEQ ID NO. 108) R-128 QSVEESGGRLVTPGTPLTLTCTVSGID ALVMTQTPASVEAAVGGTVTINCQ LSNYAMIWVRQAPGKGLEWIGVIASS ASQSIDSNLAWYQQTPGQRPKLLI GNTYYASWAKGRFSISRTSTTVDLRV YRASTLESGVSSRFKGSGSGTEYTLT TS PTTE DTATYFC AR DG FYD N VG YVY ISGVQCADAATYYCQGYYYSSSASYA AYFNIWGPGTLVTVSS (SEQ ID NO. 109) FGGGTEVVVK (SEQ ID NO. 110) R-145 QSLEESGGRLVTPGTPLTLTCTVSGFSLSNY DVVMTQTPASVSEPVGGTVTIKCQ NMGWVRQAPGKGLEWIGVIIS ASQSIGSDLAWYQQKPGQPPKLLIY SGSTYYASWVNGRFTISKTSTTVDLKI GASNLESGVPSRFKGSGSGTEYTLTI TSPTTEDTATYFCARLYVSSSGYNIW SDLECDDAATYYCQSALYGNNYIGYG GPGTLVTVSS (SEQ ID NO. Ill) FGGGTEVVVK (SEQ ID NO. 112) R-190 QSVEESGGRLVTPGTPLTLTCTASGFS AQVLTQTPASVSAAVGGTVTISCQSS LSSS YM N WVRQAPG KG LE Wl G 11 D D QRIYSANWLGWYQQKPGQPPKLLIY
[0742]
[0743] RNNTWYANWAKGRFIISKTPTTVELK RASTLASGVPSRFKGSGSGTQFTLTIS VASPTTEDTATYFCARDIDHDGDHD DLECDDAATYYCAGAYYDYRAFGGG GFYPWGPGTLVTVSS (SEQ ID NO. 113) TEVVVK (SEQ ID NO. 114)
[0744] R-191 QSLEESGGRLVTPGGSLTLTCTVSG AYDMTQTPASVEVAVGGTVTI KCQAS IDLSSYAMGWVRQAPGKGLEWIGII QSIGSNLAWYQQKPGQPPKLLIYRAS D P NTNTWYASWVKG R FTI S KTSTTV NLASGVSSRFKGSGSGTEFTLTISGVE DLKMTSLTASDTATYFCARDRYPDY CDDAATYYCQQGYSGSDIHNTFGGG SMYTFDLWGPGTLVTVSS (SEQ ID NO. TEVVVK (SEQ ID NO. 116)
[0745] 115)
[0746] R-231 QSVEESGGRLVTPGTPLTLTCTVSGI AFELTQTPASVEAAVGGTVIIKCQASQ DLSSYYMNWVRQAPGKGLEWIGII SISNYLAWYQQKPGQPPKLLIYGASTL SFGGSAYYTTWAEGRFTISKTSSTTV ASGVSSRFKGSGSGTELALTISDLECAD TLKMTSPTTEDTATYFCAKIYGYYIG AATYYCQSYYGGSSTYGSDINVFGGGT WGPSNIWGPGTLVTVSS (SEQ ID NO. EVVVK (SEQ ID NO. 118)
[0747] 117)
[0748] R-255 QSLEESGGRLVTPGTPLTLTCTASGF AAVLTQTPSPVSAAVGGTVTISCQASQ SLSTYYMSWVRQAPGKGLEYIGYIA SVYGNNQLSWYQQKPGQPPKLLIYDAS SGGNTYYATWAKGRFTISKTSTTVDL TLASGVPSRFSGSGSGTQFALTISDLEC KITSPTTEDTATYFCARVQTYTAVGYA DDAATYFCQGGYSSITDTIAFGGGTEV IAKGYFNLWGQGTLVTVSS (SEQ ID NO. WK (SEQ ID NO. 120)
[0749] 119)
[0750] R-ll QSLEESGGRLVTPGTPLTL AAVLTQTPSPVSAAVGGTV TCTASG FS LSSYYM S WVR Tl NCQASQSVYG N N QLSW QAPGKGLEYIGYITSGGNT YQQKPGQPPKLLIYGASTLA YYASWANGRFTISKTSTAV SGVPSRFKGSGSGTQFTLTI GLKITSPTIEDTATYFCARV SDLECDDAATYYCQGGYSS QTYDTIAIGVFNLWGQGT ITDTIAFGGGTEVVVK (SEQ ID NO. 273) LVTVSS (SEQ ID NO. 272)
[0751] R-123 QSVEESGGRLVTPGTPLTLTCTA AQVLTQTPASVSAAVGGTVTISCQ SGLSLSNSYMNWVRQAPGKGL SSQRIYSANWLGWYQQKPGQPP EWIGIIDDRNNTWYANWAKGR KLLIYRASTLASGVPSRFKGSGSGT
[0752] F 1 IS KTPTTVE LKVAS PTTE DTA QFTLTISDLECDDAATYYCAGAYYD TYFCARDIDHDGDHDGFYPW YRAFGGGTEVVVK (SEQ ID NO. 275) GPGTLVTVSS (SEQ ID NO. 274)
[0753]
[0754] M-282 QVQLQQPGSELVRPGASVKLSCK QI VLTQS P Al M S AS PG E KVTMTCS ARS ASGYTFNTYWMHWVRQRPGQGL SVNYMHWYQQKSGTSPKRWICDTSK EWIGTIYPAIGHTNYDDKFKSRATLT LASGVPARFSGSGSGTSYSLTISSMEAE VDTSSSTAYMQLSSLTSEDSAVYYC DAATYYCQQWSSDPLTFGAGTKLELK TRSGFDWGQGTSVAVSS (SEQ ID NO. (SEQ ID NO. 331) 330)
[0755] R-31 QSVEESGGRLVTPGTPLTLACTVSG DIVMTQTPASVEAAVGGTVTIKCQASQ FSLNSYYMSWVRQAPGKGLEWIGII SIGSNLAWYQQKPGQPPKLLIYRASTL YAGSGTTWYASWVKGRFTISKTSTTV ASGVPSRFKGSRSGTQFTLTISDLEC DLKITSPTTEDTATYFCARQYADSAG ADAATYYCQGYHYDISSGYDFAFGG YGYVDTFDPWGPGTLVTVSS (SEQ ID NO. GTEVVVK (SEQ ID NO. 333) 332)
[0756] R-75 QSVEESGGRLVTPGTPLTLTCTVSGF AQVLTQTASSVSAAVGGTVTI NCQSSQ SLSSYAMGWVRQAPGKGLEWIGIIF SVYANNWLSWYQQKPGQPPKLLIYLA EDGNTYYATWAKGRFTISKTSSTTVD STLASGVPSRFKGSGSGTQFTLTISDLE LKVTSLTADDTATYFCASVNFNIWG CDDAATYYCQGGYSSNIYPFGGGTEV PGTLVTVSS (SEQ ID NO. 334) WK (SEQ ID NO. 335)
[0757] R-171 QSVEESGGRLVTPGTPLTLTCTASG DIVMTQTPASVEAAVGGTVTIKCQASQ FSLSSGYMSWVRQAPGKGLEWIGI SAGNTLAWYQQKPGQPPKLLIYRASTL IDTGSGSTWYASWVKGRFTISKTSTT ASGVPSRFSGSGYGTEFTLTISDLECAD VDLKMTSPTTEDTATYFCARTYYDSN AASYYCQSYDYSHGFSYDFAFGGGTE GYAYVDVFDSWGPGTLVTVSS (SEQ ID VVVK (SEQ ID NO. 337)
[0758] NO. 336)
[0759] R-185 QSVKESGGGLFKPTDTLTLTCTVSG AQVLTQTPSPVSAAVGGTVTINCQAS IDLSSNVISWVRQAPGKGLEWIGDI QSVYKNNYLAWYQQKPGQPPKLLI YSDGATYCASWAKGRCTISKTSTTV YYASTLASGVPSRFKGSGSGTQFTLT DLKITSPTTEDTATYFCAKIGYKTGTI ISGVQCDDAATYYCQGEFSCSSAD WGPGTLVTISS (SEQ ID NO. 338) CIAFGGGTEVVVK (SEQ ID NO. 339)
[0760] R-212 QSVEESGGRLVTPGTPLTLTCTVSG AAVLTQTPSPVSAAVGGTVSISCQSS FSLSSYGMIWVRQAPGEGLEYIGW QSVYNNNALSWFQQKPGQPPKLLI
[0761]
[0762] MDLDGRTWYASWAKGRFTISKTSTT YKASTLASGVPSRFKGRGSGTQFTLT VDLKITSPTTEDTATYFCARPGYNTG ISDVQCDDAATYYCTGDYSSASDIT IWLWGQGTLVTVSS (SEQ ID NO. 340) FGGGTEVVVK (SEQ ID NO. 341)
[0763] R-240 QSLEESGGRLVTPGTPLTLTCTASGF ALVMTQTPSPVSAAVGGTVTINCQ SLSTYAMNWVRQAPGKGLEWIGIIDA ASQN 1 ESYLAWYQQKPGQPPN L GGAAYYASWAKGRITISKTSTTVDLRI LIYAASNLASGVPSRFKGSGSGT TSPTTEDTATYFCARVYDGYPYAYAYH QFTLTINGVQCDDAATYYCQGY GMDLWGPGTLVTVSS (SEQ ID NO. 342) DSDYINGFGGGTEVVVK (SEQ ID NO. 343)
[0764] R-293 QSLEESGGRLVKPDESLTLTCTASGF AQVLTQTPSSVSAAVGGTVTINCQ SLSNCWM AWVRQAPGM ELDWIGW SSQSVSVNRLSWFQQKPGQPP ISPDGKAYYATWTKGRFTISKTSTTVD KLLIYDASKLISGVPWRFSGSGSR LKITSPTTEDTATHFCARYFFFDNTAIF TQFTLTISGVQCDDAATYYCAAEY DSWGPGTLVTVSS (SEQ ID NO. 344) TGAIYTFGGGTEVVVK (SEQ ID NO. 345)
[0765] R-561 QSLEESGGRLVTPGTPLTLTCTVSGF AQVLTQTVSPVSAAVGGTVTISCQ SLSSYIMSWVRQAPGKGLEWIGVIS ASQSVYGNNWLAWVQQKPGQP GSVNTNYATWANGRFTISKTSTTVDL PKRLIYSASTLDSGVPSRFKGSGS E ITS PTI E DTATYFC AR AD LG LWGQG GTQFTLTIRDLECDDAATYYCAGG TLVTVSS (SEQ ID NO. 346) YSGDLYVFGGGTEVVVK (SEQ ID NO. 347)
[0766] EQQLVESGGGLVQPGGSLRLSCAVSGFSLS DVQMTQSPSSVSASVGDRVTITCRASQSIGS NYNMGWVRQAPGKGLEWIGVIISSGSTYY DLAWYQQKPGKAPKLLIYGASNLESGVPSRF REA-001_A_019 ASS VKG R FTI SKTSSTVD LYLQM N S LR AE DT SGSGSGTEYTLTISSLQPEDFATYYCQSALYGN (humanized-vl) AVYFCARLYVSSSGYNIWGQGTLVTVSS NYIGYGFGGGTELEIK (SEQ ID NO. 359) (SEQ ID NO. 357)
[0767] EQQLVESGGGLVQPGGSLRLSCAVSGFSLS DVQMTQSPSSVSASVGDRVTITCRASQSIGS NYNMGWVRQAPGKGLEWIGVIISSGSTYY DLAWYQQKPGKAPKLLIYGASNLESGVPSRF REA-001_A_020 ASS VKG R FTI SKTSSTVD LYLQM N S LR AE DT SGSGSGTDYTLTISSLQPEDFATYYCQSALYG (humanized-v2) AVYFCARLYVSSSGYNIWGQGTLVTVSS NNYIGYGFGGGTKLEIK (SEQ ID NO. 360)
[0768] (SEQ ID NO. 357)
[0769] EQQLVESGGGLVQPGGSLRLSCAVSGFSLS DVQMTQSPSSLSASVGDRVTITCRASQSIGS NYNMGWVRQAPGKGLEWIGVIISSGSTYY DLAWYQQKPGKAPKLLIYGASNLESGVPSRF REA-001_A_021 ASS VKG R FTI SKTSSTVD LYLQM N S LR AE DT SGSGSGTEYTLTISSLQPEDFATYYCQSALYGN (humanized-v3) AVYFCARLYVSSSGYNIWGQGTLVTVSS NYIGYGFGGGTELEIK (SEQ ID NO. 361) (SEQ ID NO. 357)
[0770]
[0771] EQQLVESGGGLVQPGGSLRLSCAVSGFSLS AVQMTQS PSS LS ASVG D RVTITCRASQSIGS NYNMGWVRQAPGKGLEWIGVIISSGSTYY DLAWYQQKPGKAPKLLIYGASNLESGVPSRF REA-001_A_022 ASS VKG R FTI SKTSSTVD LYLQM N S LR AE DT SGSGSGTDYTLTISSLQPEDFATYYCQSALYG (humanized-v4) AVYFCARLYVSSSGYNIWGQGTLVTVSS NNYIGYGFGGGTKLEIK (SEQ ID NO. 362) (SEQ ID NO. 357)
[0772] EQQLVESGGGLVQPGGSLRLSCAVSGFSLS DVQMTQSPSSVSASVGDRVTITCRASQSIGS NYNMGWVRQAPGKGLEWVGVIISSGSTY DLAWYQQKPGKAPKLLIYGASNLESGVPSRF REA-001_A_023 YASSVKGRFTISKDSSKNTLYLQMNSLRAED SGSGSGTEYTLTISSLQPEDFATYYCQSALYGN (humanized-v5) TAVYYCARLYVSSSGYNIWGQGTLVTVSS NYIGYGFGGGTELEIK (SEQ ID NO. 359) (SEQ ID NO. 358)
[0773] EQQLVESGGGLVQPGGSLRLSCAVSGFSLS DVQMTQSPSSVSASVGDRVTITCRASQSIGS NYNMGWVRQAPGKGLEWVGVIISSGSTY REA-001_A_024 DLAWYQQKPGKAPKLLIYGASNLESGVPSRF YASSVKGRFTISKDSSKNTLYLQMNSLRAED
[0774] (humanized-v6) TAVYYCARLYVSSSGYNIWGQGTLVTVSS SGSGSGTDYTLTISSLQPEDFATYYCQSALYG (SEQ ID NO. 358)
[0775] NNYIGYGFGGGTKLEIK (SEQ ID NO. 360) EQQLVESGGGLVQPGGSLRLSCAVSGFSLS DVQMTQSPSSLSASVGDRVTITCRASQSIGS NYNMGWVRQAPGKGLEWVGVIISSGSTY DLAWYQQKPGKAPKLLIYGASNLESGVPSRF REA-001_A_025 YASSVKGRFTISKDSSKNTLYLQMNSLRAED SGSGSGTEYTLTISSLQPEDFATYYCQSALYGN (humanized-v7) TAVYYCARLYVSSSGYNIWGQGTLVTVSS NYIGYGFGGGTELEIK (SEQ ID NO. 361) (SEQ ID NO. 358)
[0776] EQQLVESGGGLVQPGGSLRLSCAVSGFSLS AVQMTQS PSS LS ASVG D RVTITCRASQSIGS NYNMGWVRQAPGKGLEWVGVIISSGSTY DLAWYQQKPGKAPKLLIYGASNLESGVPSRF REA-001_A_026 YASSVKGRFTISKDSSKNTLYLQMNSLRAED SGSGSGTDYTLTISSLQPEDFATYYCQSALYG (humanized-v8) TAVYYCARLYVSSSGYNIWGQGTLVTVSS NNYIGYGFGGGTKLEIK (SEQ ID NO. 362) (SEQ ID NO. 358)
[0777]
[0778] Each of the VH / VL combinations in Table 8 may be paired with a heavy chain constant region comprising an Fc region, and a light chain constant region. In such embodiments the heavy chain constant region comprises the sequence of SEQ ID NO. 375 and the light chain region comprises the sequence of SEQ ID NO. 377.
[0779] Each of the VH / VL combinations in Table 8 may be paired with a heavy chain constant region comprising an Fc region comprising the mutation K439E, and a light chain constant region. In such embodiments the heavy chain constant region comprises the sequence of SEQ ID NO. 376 and the light chain region comprises the sequence of SEQ ID NO. 377.
[0780] Each of the VH / VL combinations in Table 8 may be paired with a heavy chain constant region comprising an afucosylated Fc region, and a light chain constant region. In such embodiments the heavy chain constant region comprises the sequence of SEQ ID NO. 375 (afucosylated) and the light chain region comprises the sequence of SEQ ID NO. 377.Each of the VH / VL combinations in Table 8 may be paired with a heavy chain constant region comprising an afucosylated Fc region comprising the mutation K439E, and a light chain constant region. In such embodiments the heavy chain constant region comprises the sequence of SEQ ID NO. 376 (afucosylated) and the light chain region comprises the sequence of SEQ ID NO. 377.
[0781] Table 9. Other sequences
[0782] Description Sequence
[0783] MDQQAIYAELNLPTDSGPESSSPSSLPRDVCQGS PWHQFALKLSCAG 11 LLVLVVTG LSVSVTSLIQKSS IEKCSVDIQQSRNKTTERPGLLNCPIYWQQLREKC
[0784] hCD161 full sequence LLFSHTVNPWNNSLADCSTKESSLLLIRDKDELIHT QNLIRDKAILFWIGLNFSLSEKNWKWINGSFLNSN DLEIRGDAKENSCISISQTSVYSEYCSTEIRWICQKEL TPVRNKVYPDS (SEQ ID NO. 256) EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMS WVRQAPGKGLEWVSTISGSGGSTYYADSVKGRF KW1.3.12 (Dana Faber) VH
[0785] TISRDNSRNTLYLQMNSLRAEDTAVYYCARGGLIP SGFDYWGQGTLVTVSS (SEQ ID NO. 257) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWY QQKPGKAPKLLIYAASSLLSGVPSRFSGSGSGTDFT KW1.3.12 (Dana Faber) VL LTI SS LQP E D F ATYYCQQTYS AP LTFGQGTKVE 1 K
[0786] (SEQ ID NO. 258)
[0787] EVQLVESGGGLVQPGGSLRLSCAASGSTFSSYAMSWVRQAPGK GLEWVSTISGSGGSTYYADSVKGRFTISRDNSRNTLYLQMNSL KW1.2.1 (Dana Faber) VH
[0788] RAEDTAVYYCARGGLIPSGFDYWGQGTLVTVSS (SEQ ID NO.
[0789] 363) DIQMTQSPSSPSASVGDRVTITCRASQSISSYLNWYQQKPGKA KW1.2.1 (Dana Faber) VL PKLLIYAASSLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATY YCQQTYSTPLTFGQGTKVEIK (SEQ ID NO. 364) EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGK KW7.3.7 (Dana Faber) VH
[0790] GLEWVSATSGSGGSTYYADSAKGRFTISRDNSKNTLYLQMNSL
[0791]
[0792] RAEDTAVYYCARGGYLPDAFDYWGRGTLVTVSS (SEQ ID NO.
[0793] 365)
[0794] D 1 QMTQS PSS LS ASVG D RVTITCWASQS ISSYLN WYQQE PG KA KW7.3.7 (Dana Faber) VL PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATY YCQQTYSTPLTFGQGTKVEIK (SEQ ID NO. 366) QVQLVQSGAEVKKPGASVKVSCKASGYSFTGYWMHWVRQA
[0795] Hu47A5H2-ll (Brigham & PGQGLEWMGMIHPSDSETRLNQKFKDRVTMTVDKSTSTVY Women's) VH
[0796] MELSSLRSEDTAVYYCASEGLRRGSFAYWGQGTLVTVSS
[0797] (SEQ ID NO. 367) DIVLTQSPDSLAVSLGERATINCRASESVDNYGMTFMSWF
[0798] Hu47A5H2-ll (Brigham & QQKPGQPPKLLIYAASNQGSGVPDRFSGSGSGTDFTLTISSLQAE Women's) VL
[0799] DVAVY YCQQSKEVPYTFGQGTKLEIK
[0800] (SEQ ID NO. 368) QVQLVQSGAEVKKPGASVKVSCKASGYTFIDYYINWVRQA
[0801] Hu50A8F2-04 (Brigham & PGQGLEWMGWIFPGSGHTKYNENFKGRVTMTRDTSTSTVY Women's) VH
[0802] MELSSLRSEDTAVYYCARGDRSALGYFDYWGQGTTVTVSS
[0803] (SEQ ID NO. 369)
[0804] D 1 QLTQS PSS LS ASVG D RVTITCTASSS VSSTYLH WYQQKPG KS P KLLIY
[0805] Hu50A8F2-04 (Brigham &
[0806] Women's) VL STSNLASGVPSRFSGSGSGTDYTLTISSLQPEDAATYYCHQYHRSP LTFG QGTKLEIK
[0807] (SEQ ID NO. 370) DVQLQESGPGQVKPSQSLSLTCTVTGYSLTSDFAWNWIRQ FPGNRLEWMGDIRYSGSTDYNPSLKGRSSITRDTSKNQFFLQLN
[0808] 22F10G3 (Brigham & Women's)
[0809] VH SVTTED TATYYCARGG YYGYDEGYPM DYWGQGTSVTVSS
[0810] (SEQ ID NO. 371)
[0811] NIVLTQSPAS LAVSLGQRATISCRASESVDVYGNSFMHWY QQKTGQPPKLLIYLAFNLKSGVPARFSGSGSRTDFTLTIDPVEAD
[0812] 22F10G3 (Brigham & Women's)
[0813] VL DAATY YCQQNNEDPFTFGSGTKLEIK
[0814] (SEQ ID NO. 372) EVQLLESGGGLVQPGGSLRLSCAASGFTFSPYAMSWVRQAPGK GLEWVSAISASGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLR
[0815] Ab9 (Immunitas) VH
[0816] AEDTAVYYCAKPLDSSFWADFDLWGRGTLVTVSS
[0817] (SEQ ID NO. 373)
[0818] Ab9 (Immunitas) VL D 1 QLTQS PSS VS AS VG D R VT ITC R ASQG 1 SS W L AWYQQK PG K
[0819]
[0820] APKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATY YCQQHSVLPITFGGGTKVEIK
[0821] (SEQ ID NO. 374) ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ
[0822] Constant Heavy domain (CH) - human YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK (SEQ ID NO. 375) ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ
[0823] Constant Heavy domain (CH)
[0824] K439E - human YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQESLSLSPGK (SEQ ID NO. 376) RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVD
[0825] Constant Light domain (CL) NALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV human kappa
[0826] THQGLSSPVTKSFNRGEC (SEQ ID NO. 377)
[0827]
Claims
CLAIMS1. An antibody molecule or antigen binding fragment which binds to and depletes CD161+ cells and which does not significantly inhibit CD161-CLEC2D binding.
2. The antibody molecule or antigen binding fragment according to claim 1, wherein the antibody or antigen binding fragment binds specifically to CD161.
3. The antibody molecule or antigen binding fragment according to claim 1 or 1, wherein the antibody or antigen binding fragment depletes at least about 35%, at least about 40%, at least about 45% or at least about 50% of a population of CD161+ cells in a tissue or in a sample.
4. The antibody molecule or antigen binding fragment according to any preceding claim, wherein the antibody or antigen binding fragment has an Inhibitory Concentration 50% (IC5o) for inhibiting CD161-CLEC2D binding of at least about 200 ng / ml, at least about 500 ng / ml, at least about 1000 ng / ml, at least about 2000 ng / ml, at least about 5000 ng / ml or at least about 10,000 ng / ml.
5. The antibody molecule or antigen binding fragment according to any preceding claim, wherein the antibody or antigen binding fragment has an Imax for CD161-CLEC2D inhibition of less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 15%, or less than about 10% of the baseline CD161-CLEC2D binding activity at an antibody concentration of lpg / ml.
6. The antibody molecule or antigen binding fragment according to any of claims 4 or 5, wherein the antibody or antigen binding fragment has an on-cell binding affinity (Kd) for CD161 of less than about 20nm, or less than about lOnm, or less than about 6nm.
7. The antibody molecule or antigen binding fragment according to any of the preceding claims, comprising:a) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 1, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 2 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 3, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 4, a light chain complementarity determining region 2 (VLCDR2)amino acid sequence of SEQ ID NO. 5 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 6; orb) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 7 , a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 8 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 9, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 10, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 11 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 12;c) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 13, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 14, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 15 and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 16, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 17 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 18; ord) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 19, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 20 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 21, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 22, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 23 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 24;e) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 25, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 26 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 27, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 28, a light chain complementarity determining region 2 (VLCDR2)amino acid sequence of SEQ ID NO. 29, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 30;f) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 31, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 32 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 33, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 34, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 35, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 36; org) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 37, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 38 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 39, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 40, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 41, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 42; orh) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 43, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 44, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 45, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 46, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 47, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 48; ori) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 49, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 50 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 51, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 52, a light chain complementarity determining region 2 (VLCDR2)amino acid sequence of SEQ ID NO. 53, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 54; orj) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 55, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 56 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 57, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 58, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 59, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 60; ork) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 61, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 62, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 63, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 64, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 65, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 66; orl) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 348 (IMGT), a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 349 (IMGT), and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 350 (IMGT), and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 351 (IMGT), a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 352 (IMGT), and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 353 (IMGT); orm) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 67, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 68 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 69, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acidsequence of SEQ ID NO. 70, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 71, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 72; orn) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 73, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 74 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 75, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence SEQ ID NO. 76, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 77, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 78; oro) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 79, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 80 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 81, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 82, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 83, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 84; orp) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 85, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 86, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 87 and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 88, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 89 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 90; orq) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 260, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 261, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 262 and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) aminoacid sequence of SEQ ID NO. 263, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 264 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 265; orr) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 266, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 267, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 268 and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 269, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 270 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 271, ors) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 276, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. Til and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 278, and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 279, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 280 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 281; ort) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 282, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 283 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 284, and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 285, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 286 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 287; oru) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 288, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 289 and a heavy chain complementarity determining region 3 (VHCDR3)amino acid sequence of SEQ ID NO. 290, and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 291, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 292 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 293; orv) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 294, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 295 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 296, and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 297, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 298 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 299; orw) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 300, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 301 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 302, and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 303, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 304 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 305; orx) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 306, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 307 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 308, and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 309, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 310 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 311; ory) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 312, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 313 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 314, and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 315, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 316 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 317; orz) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 318, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 319 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 320, and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 321, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 322 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 323; oraa) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 324, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 325 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 326, and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 327, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 328 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 329; orbb) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 61, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 354 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 63, and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1)amino acid sequence of SEQ ID NO. 355, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 65 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 66; orcc) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 348 (IMGT), a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 356 (IMGT) and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 350 (IMGT), and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 351 (IMGT), a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 352 (IMGT) and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 353 (IMGT).
8. The antibody molecule or antigen binding fragment according to any of the preceding claims, comprising:a) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 1, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 2 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 3, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 4, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 5 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 6; orb) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 266, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 267, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 268 and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 269, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 270 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 271; orc) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 61, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 62, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 63, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 64, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 65, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 66;d) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 348 (IMGT), a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 349 (IMGT), and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 350 (IMGT), and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 351 (IMGT), a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 352 (IMGT), and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 353 (IMGT); ore) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 67, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 68 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 69, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 70, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 71, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 72;f) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 260, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 261, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 262 and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 263, a light chain complementarity determining region 2(VLCDR2) amino acid sequence of SEQ ID NO. 264 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 265; org) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 25, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 26 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 27, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 28, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 29, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 30;h) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 37, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 38 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 39, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 40, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 41, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 42; ori) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 73, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 74 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence SEQ ID NO. 75, and a light chain variable region (VL) comprising one, two or three of a light chain complementarity determining region 1 (VLCDR1) amino acid sequence SEQ ID NO. 76, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 77, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 78;j) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 61, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 354 and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 63, and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 355, a light chain complementarity determiningregion 2 (VLCDR2) amino acid sequence of SEQ ID NO. 65 and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 66; ork) a heavy chain variable region (VH) comprising one, two or three of a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO. 348 (IMGT), a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO. 356 (IMGT) and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO. 350 (IMGT), and one, two or three of a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO. 351 (IMGT), a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO. 352 (IMGT) and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO. 353 (IMGT).
9. The antibody molecule or antigen binding fragment according to any of the preceding claims, comprising:a) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 91 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 92; orb) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 93 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 94; orc) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 95 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 96; ord) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 97 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 98; ore) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 99 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 100; orf) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 101 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 102; org) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 103 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 104; orh) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 105 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 106; ori) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 107 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 108; orj) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 109 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 110; ork) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 1ll and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 112; orl) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 113 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 114; orm) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 115 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 116; orn) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 117 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 118; oro) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 119 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 120; orp) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 272 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 273; orq) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 274 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 275, orr) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 330 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 331; ors) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 332 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 333; ort) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 334 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 335; oru) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 336 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 337; orv) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 338 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 339; orw) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 340 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 341; orx) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 342 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 343; ory) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 344 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 345; orz) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO. 346 and / or a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO. 347; oraa) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 357 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 359; orbb) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 357 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 360; orcc) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 357 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 361; ordd) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 357 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 362; oree) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 358 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 359; orff) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 358 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 360; orgg) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 358 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 361; orhh) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 358 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 362.
10. The antibody molecule or antigen binding fragment according to any of the preceding claims, comprising:a) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 91 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 92; orb) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 274 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 275;c) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 1ll and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 112; ord) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 113 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 114; ore) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 272 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 273; orf) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 99 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 100; org) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 103 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 104; orh) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 115 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 116.
11. The antibody molecule or antigen binding fragment according to any of claims 1 to 9, comprising: a) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 357 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 359; orb) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 357 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 360; orc) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 357 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 361; ord) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 357 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 362; ore) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 358 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 359; orf) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 358 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 360; org) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 358 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 361; orh) a heavy chain variable region (VH) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 358 and / or a light chain variable region (VL) comprising an amino acid sequence having at least about 90% identity to SEQ ID NO. 362.
12. The antibody molecule or antigen binding fragment according to any of the preceding claims, wherein the antibody or antigen binding fragment comprises a heavy chain variable region (VH) comprising an amino acid sequence which has at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98% or at least about 99% identity to SEQ ID NOS. 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 272, 274, 357 or 358.
13. The antibody molecule or antigen binding fragment according to any of the preceding claims, wherein the antibody or antigen binding fragment comprises a heavy chain variable region (VH) comprising an amino acid sequence which has at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98% or at least about 99% identity to SEQ ID NOs. 91, 99, 103, 111, 113, 115, 272, 274, 357 or 358.
14. The antibody molecule or antigen binding fragment according to any of the preceding claims, wherein the antibody or antigen binding fragment comprises a light chain variable region (VL) comprising an amino acid sequence which has at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98% or at least about 99% identity to SEQ ID NOS. 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 273,275, 359, 360, 361 or 362.
15. The antibody molecule or antigen binding fragment according to any of the preceding claims, wherein the antibody or antigen binding fragment comprises a light chain variable region (VL) comprising an amino acid sequence which has at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98% or at least about 99% identity to SEQ ID NOS. 92, 100, 104, 112, 114, 116, 273, 275, 359, 360, 361 or 362.
16. The antibody molecule or antigen binding fragment according to any of the preceding claims, wherein the antibody molecule or antigen binding fragment is monoclonal or polyclonal.
17. The antibody molecule or antigen binding fragment according to any of the preceding claims, wherein the antibody binding fragment is selected from the group consisting of a monovalent antibody, a Fab, a Fab', a F(ab')2, a single chain variable fragment (scFv), an antibody domain, a nanobody (VHH), a Shark VNAR, a minibody and an scFv-FC; and variations thereof.
18. The antibody molecule or antigen binding fragment according to any of the preceding claims, wherein the antibody molecule or antigen binding fragment comprises a heavy chain constant region of IgGl or lgG4.
19. The antibody molecule or antigen binding fragment according to any of the preceding claims, wherein the antibody molecule or antigen binding fragment comprises an Fc region, optionally a modified Fc region.
20. The antibody molecule or antigen binding fragment according to claim 19, wherein the Fc region is afucosylated.
21. The antibody molecule or antigen binding fragment according to claim 19 or 20, wherein Fc region comprises the K439E mutation.
22. The antibody molecule or antigen binding fragment according to any of the preceding claims, wherein the antibody molecule or antigen binding fragment comprises a heavy chain constant region comprising the sequence of SEQ ID NO. 375 or SEQ ID NO. 376.
23. The antibody molecule or antigen binding fragment according to any of the preceding claims, wherein the antibody molecule or antigen binding fragment comprises a light chain kappa constant region.
24. The antibody molecule or antigen binding fragment according to any of the preceding claims, wherein the antibody molecule or antigen binding fragment comprises a light chain constant region comprising the sequence of SEQ ID NO. 377.
25. The antibody molecule or antigen binding fragment according to any claims 1 to 22, wherein the antibody molecule or antigen binding fragment comprises a light chain lambda constant region.
26. The antibody molecule or antigen binding fragment according to any of the preceding claims, wherein the antibody molecule or antigen binding fragment is a rat antibody, a human antibody or a chimeric antibody.
27. The antibody molecule or antigen binding fragment according to any of the preceding claims, wherein the antibody molecule or antigen binding fragment is humanized, optimised, and / or de-immunized.
28. The antibody molecule or antigen binding fragment according to any of the preceding claims, wherein the antibody molecule or antigen binding fragment is monospecific.
29. The antibody molecule or antigen binding fragment according to any of claims 1 to 21, wherein the antibody molecule or antigen binding fragment is multispecific, optionally bispecific.
30. The antibody molecule or antigen binding fragment according to any of claims 1 to 29, wherein the antibody or antigen binding fragment does not compete for binding with the antibody KW1.3.12 disclosed in WQ2021 / 080682 and having the VH sequence of SEQ ID NO. 257 and the VL sequence of SEQ ID NO.258.
31. A nucleic acid encoding an antibody molecule or antigen binding fragment according to any of the preceding claims.
32. An expression vector comprising a nucleic acid according to claim 31.
33. A host cell comprising an expression vector according to claim 32.
34. A pharmaceutical composition comprising an antibody molecule or antigen binding fragment according to any of claims 1 to 30, a nucleic acid according to claim 31, an expression vector according to claim 31, and / or a host cell according to claim 33.
35. The pharmaceutical composition according to claim 34, further comprising a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.
36. A method of producing an antibody molecule or antigen binding fragment according to any of claims 1 to 30, the method comprising culturing a host cell according to claim 33 under conditions suitable for gene expression.
37. A method of treating or preventing an immune-mediated inflammatory disease (IM ID) in a subject, the method comprising administering to the subject an antibody molecule or antigen binding fragment according to any of claims 1 to 30 or the pharmaceutical composition according to claim 34 or 35.
38. The method of treating or preventing an IM ID according to claim 37, wherein administration of the antibody or antigen binding fragment of claims 1 to 30 or the composition of claim 34 or 35 reduces expression of at least one of IL-17 (A / F), IL-23, IL-22, IFNy, IL-26, TNFa, IL-2, IL-21 and / or GM-CSF in the subject.
39. The method of treating or preventing an I M I D according to any of claims 37 or 38, wherein the I M ID is mediated by at least one of IL-17 (A / F), IL-23, IL-22, IFNy, IL-26, TNFa, IL-2, IL-21 and / or GM-CSF, preferably IL-17 and / or IL-23.
40. The method of treating or preventing an I M ID according to any of claims 37 to 39, wherein the I M ID is Hidradenitis Suppurativa (HS), Psoriasis (PsO), Psoriatic Arthritis (PsA), Axial spondyloarthritis (AxSpA), Inflammatory bowel disease (IBD), Uveitis, preferably HS.
41. The method of treating or preventing an I M I D or auto-immune disease according to any of claims 37 to 40, wherein the IM ID is a T-cell mediated disease.
42. The method of treating or preventing an I M ID according to any of claims 37 to 41, wherein the I M ID is a B-cell mediated disease.
43. An antibody or antigen binding fragment of any one of claims 1 to 30, for use in the methods of any one of claims 37 to 42.
44. A composition of claim 34 or 35, for use in the methods of any one of claims 37 to 42.
